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1.1. INTRODUCTION 
The anxiety syndrom "panic disorder" is at the moment subject of intensive 
biological psychiatrical research. The syndrom consists of panic attacks 
(intense fear) with several somatic symptoms (dizziness, palpitations, 
hyperventilation). Most patients develop some degree of anticipatory anxiety 
(i.e. fear of having anothe'r panic attack). A number of panic disorder 
patients develop agoraphobic symptoms. These symptoms may be described as fear 
to be in a situation in which no help is present if something (e.g. a panic 
attack) happens to the patient. 
It has been described that panic anxiety is benzodiazepine resistant 
(Sheehan (1982), McNair and Kahn (1981)), but anti-depressants have been shown 
to have anti-panic properties (Klein (1967), Zitrin et al (1978)). The 
therapeutic efficacy seems to correlate with the reuptake inhibition of 
serotonin (5-hydroxytryptamine (5-HT)) (Den Boer (1988)). The· triazolo-
benzodiazepine alprazolam has also a beneficial effect in panic disorder 
(Ballenger et al (1988)). It is less known that the GABAB receptor agonist 
baclofen also possesses anti-panic properties (Pepplinkhuizen and Bruinvels 
(1978), Breslow et al. (1989)). 
In order to investigate the mechanism responsible for the anxiolytic effect 
of baclofen, an animal behavioural model has been developed in which this 
compound is effective. Chapter I reviews the literature on the GABA-ergic 
system, 5-HT system, the involvement of several neurotransmitters in anxiety, 
various animal models for anxiety and panic disorder. The aim of the 
experiments was to investigate the relationship between baclofen on one hand, 
and the GABAAjbenzodiazepine receptor chloride channel complex and the 5-HT 
system on the other hand, using extinction of conflict behaviour as a tool. 
The Chapters II to V describe the experiments which try to shed more light on 
two possible mechanisms, namely GABAA and/or 5-HT involvement, by which 
baclofen might mediate its effect on extinction of conflict behaviour. 
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L2. THE GABA-ERGIC SYSTEM 
1.2.1 The neurotransmitter GABA. 
The amino acid T-aminobutyric acid (GABA) is the most important inhibitory 
neurotransmitter in the central nervous system. Anatomical studies suggest 
that GABA is localized primarily in small interneurons throughout the central 
nervous system but there are also GABA-ergic projections linking the corpus 
striatum and nucleus accumbens to other brain regions like the globus 
pallidus, substantia nigra and interpeduncular nucleus (Scheel-Kruger (1983)). 
It is estimated that 10 to 40 % of all terminals in the cerebral cortex, 
hippocampus and substantia nigra are GABA-ergic (Iversen and Bloom (1972), 
Schon and Iversen (1974)). In the neocortex it is shown that the GABA 
containing neurons are almost exclusively local neurons and are distributed 
through all layers (Ottersen and Storm-Mathisen (1984), Reiffenstein and Neil 
(1974), Ribak (1978)). The hippocampus also contains local GABA-ergic neurons, 
and is most densely present in the pyramidal/granular layer and the molecular 
layer (Storm-Mathisen and Fonnum (1971)). The Purkinje, stellate, basket and 
Golgi cells in the cerebellum are identified as being GABA-ergic (Ottersen and 
Storm-Mathisen (1984), Fonnum et al. (1970), McLaughlin et al. (1974)). In the 
medulla the evidence of the existence of GABA-ergic neurons is most impressive 
in the raphe nuclei (Belin et al. (1979), Vincent et al. (1980)). It has been 
reported that the neurotransmitters serotonin (5-hydroxytryptamine, 5-HT) and 
GABA coexist in some raphe neurons (Belin et al. (1983)). 
1.2.2. GABA receptors 
GABA receptors were initially defined on the basis of their sensitivity to 
inhibition by bicuculline and picrotoxin (Curtis et al. (1971)). More 
recently, it has been shown that receptors for GABA in the central nervous 
system are not of an homogenous type. Three types of GABA receptors have been 
identified: GABAA receptors are bicuculline sensitive and baclofen (Lioresal, 
~-(p-chlorophenyl)GABA) insensitive while GABAB receptors are bicuculline 
insensitive and baclofen sensitive (Bowery et al. (1980)). A third type, 
GABAc, has been proposed which is both bicuculline and baclofen insensitive 
(Johnston (1986)). 
Radioligand binding studies show that receptors for GABA are present on 
virtually all neurons of the central nervous system (Fonnum (1987)). On the 
whole, the GABAA receptors outnumber GABAB receptors in the rat central 
nervous system (Bowery et al. (1987)). However, autoradiographic studies 
indicate the reverse in some specific areas such as the interpeduncular 
nucleus, fasciculus retroflexus, medial habenular nucleus, substantia 
gelatinosa, superior colliculus, globus pallidus, lateral amygdaloid nucleus, 
pontine nucleus, raphe magnus and molecular layer of the cerebellum. (Bowery 
et al. (1987)). 
1.2.2.A The GABAA/benzodiazepine chloride channel complex. 
The GABAA receptor has been extensively investigated. GABAA receptors can 
be subdivided in a receptor with a high (dissociation constant 3-10 nM) and a 
low (dissociation constant 50-120 nM) affinity for GABA (Enna and Karbon 
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(1986)). It is known that GABAA receptor activation increases chloride channel 
conductance which results in an influx of chloride ions in most of the cases 
(postsynaptic hyperpolarization), but sometimes in an outward flux 
(presynaptic depolarization) (review: Enna (1981)). The GABAA receptor can be 
subdivided in a population which is associated with the benzodiazepine 
receptor and a population which is not (Palacios et al. (1981), Unnerstal 
(1981)). It is the low affinity GABA receptor which has been shown to be 
linked with the benzodiazepine receptor (Tallman et al. (1978), Karobath and 
Sperk (1979), Skerritt et al. (1982)). On the other hand, it has been 
suggested that high and low affinity GABAA receptors represent in fact a 
single site that can exists interconvertibly in an agonist or an antagonist 
state (Maksay and Ticku (1984)). 
It appears that all GABAA receptors are associated with the chloride 
ionophore (Enna and Karbon (1986)), while most postsynaptic GABAA receptors 
form a part of the GABAAfbenzodiazepine receptor chloride channel complex. The 
three components of this complex can be characterized in vitro by radioligand 
binding assays using [3H]GABA for the GABAA rece~tor sites, [3H]benzo-
diazepines for the benzodiazepine receptors and [ H]DHP (a-dihydropicro-
toxinin) for the chloride ion site (review: Ticku (1983)). It has been shown 
that these three sites interact with eachother; the binding characterics of 
each site are under the influence of the degree of activation of the other two 
receptor sites (Enna and Karbon (1986)). 
Three kinds of benzodiazepine receptor ligands are reported: agonists (e.g. 
diazepam, chlordiazepoxide), antagonists (e.g. ROlS-1788 (Hunkeler et al. 
(1981)) and inverse agonists (e.g. methyl ~-carboline-3-carboxylate (~CCE) and 
methyl 6,7-dimethoxy-4-ethyl-~-carboline-3-carboxylate (DMCM) (Oakley and 
Jones (1980), Braestrup et al. (1982)). Benzodiazepine receptors can be 
subdivided into 2 types on basis of the affinity for the triazolopyridazine 
CL218, 872; Type 1 benzodiazepine receptors have a higher affinity for this 
compound than type 2 receptors while both types have a high affinity for 
benzodiazepines (Squires et al. (1979)). It was postulated that activation of 
type 1 benzodiazepine receptors mediates anxiolytic effects, and activation of 
type 2 benzodiazepine receptors mediates the sedative effect of these 
compounds (Lippa et al. (1979)). However, Oakley et al. (1984) reported 
sedative effects of CL 218,872 in the same dose range as its anxiolytic 
effects. Receptors for benzodiazepines are found in the highest concentrations 
in the cerebral cortex, cerebellum and amygdala, and in intermediate 
concentrations in the hippocampus, striatum and spinal cord. Type 2 receptors 
have a relatively higher density in the amygdala and hippocampus (50 %) , a 
relatively lower density in the cortex (25 %), and were virtually absent in 
the cerebellum (Braestrup and Nielsen (1980), Young et al. (1981)). 
The behavioural effects resulting from GABAA/benzodiazepine chloride 
channel complex activation are extensively documented. They concern 
anxiolytic, anti-convulsive, sedative, muscle relaxant, anti-aggressive and 
(anterograde) amnestic actions (review: File and Cooper (1985)). Clinical use 
of benzodiazepines, barbiturates, anti-epileptics etc. are a reflection of the 
properties mentioned above, e.g. anxiolysis, anti-convulsive action, hypnotic 
and spasmolytic action etc. In practice, benzodiazepines are used in all kinds 
of anxiety, however, it appears that they are most rightfully indicated in 
acute stress situations and generalized anxiety disorder. It was initially 
reported that benzo-diazepines (administered in low doses) were not active in 
panic disorder (McNair and Kahn (1981)), but recent data suggest that the high 
affinity benzodiazepine receptor agonist alprazolam, a triazolobenzodiazepine, 
and high doses of diazepam, lorazepam, bromazepam and clonazepam have 
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benificial effects in panic disorder (Ballenger et al. (1988), Beaudry et al. 
(1984), Spier et al. (1986), Noyes et al. (1984, 1988)). 
1.2.2.B The GABAB receptor 
The GABAB receptor site has been characterized more recently (Bowery et al. 
(1982)). The concept of baclofen being a selective GABAB receptor agonist came 
from studies on the peripheral nervous system, where GABA and the (-)-isomer 
of baclofen were shown to have a bicuculline-insensitive inhibitory action on 
the release of noradrenaline from atria and vas deferens (Bowery and Hudson 
(1979), Bowery et al. (1980), review: Bowery (1983)). Baclofen was designed as 
a lipophilic derivative of GABA, able to cross the blood-brain barrier. The 
localization of the GABAB receptor in comparison with the GABAA receptor 
distribution is described in 1.2.2 .. The GABAB receptor is not linked to the 
chloride channel and its binding is not modulated by benzodiazepines (Bowery 
et al. (1984)). In analogy with the GABAA receptors, high and low affinity 
GABAB receptors are described (Bowery and Hill (1981)). Early reports on the 
second messenger of the GABAB receptor indicate a blockade of calcium influx 
(Dunlap (1981)). However, later on it has also been reported that GABAB 
receptor activation causes a hyperpolarization via an increase in potassium 
conductance in the hippocampus (Newberry and Nicoll (1984)) and substantia 
nigra (Pinnock (1984)) and that this phenomenon might underly the observed 
decreased calcium influx (Ghawiler and Brown (1985)). On its turn, also the 
latter notion has been challenged in the sense that the decrease in calcium 
influx is reported to be a potassium independent phenomenon (Diesz and Lux 
(1985)). Baclofen is shown to inhibit basal adenylate cyclase activity in the 
presence and absence of forskolin in several areas of the brain, including 
hippocampus, striatum and cerebellum of rat brain membrane preparations 
(Wojcik and Neff (1983)). It is reported that GABAB receptor activation 
inhibits forskolin-stimulated adenylate cyclase activity but, in contrast, 
enhances the calcium-dependent stimulation of cAMP accumulation induced by 
adenosine, histamine, ~-adrenoceptor agonists and vasoactive intestinal 
peptide (Hill and Dolphin (1984), Enna and Karbon (1987)). This synergistic 
interaction is region-specific: it occurs in cerebral cortex, hippocampus and 
striatum, but not in spinal cord, cerebellum and pons-midbrain. The ~­
adrenoceptor-induced increase of cyclic AMP is enhanced by GABAB receptor 
activation via a GTP regulatory protein. This might also be the case 
concerning the GABAB effect on potassium channels (Asano et al. (1985), 
Andrade et al. (1986), Hill et al. (1984)). No antagonist of GABAB receptors 
is available for in vivo studies, but now reports of Bonnano et al. (1988) and 
Kerr et al. (1987) exist of in vitro antagonism by the compound phaclofen (~­
(p-chlorophenyl)-3 amino propyl phosphonic acid). The reported GABAB receptor 
activation-induced changes of neurotransmitter release (see paragraph 1.2.3.) 
might be mediated via the effects of GABAB receptor activation on potassium 
channels, calcium channels, adenylate cyclase activity or a combination of 
these factors (Dolphin (1984)). 
Several effects of GABAB receptor activation are observable in vivo: muscle 
relaxation, sedation, hypothermia (Gray et al. (1987)), anti-convulsive 
effects (Ault et al. (1986), Petersen (1983)), anti-nociception (Cutting and 
Jordan (1975)) and disruption of passive avoidance retention, (which was 
interpreted as a baclofen-induced memory consolidation deficit) (Swartzfelder 
et al. (1987)). On the other hand, it was shown by Nabeshima et al. (1988) 
that baclofen antagonized the memory consolidation deficits induced by several 
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GABA receptor antagonists. (For the effect of GABAB receptor activation in 
animal models for anxiety: see discussion). 
A number of reports exist on the effect of baclofen in humans. The only 
clinical use on which there is a consensus appears to be spasticity (Jones et 
al. (1970), Young and Delwaide (1981)). Other reports concern a treatment for 
restless legs (Guilleminault and Flagg (1984), convulsant and (seldom) anti-
convulsant effects (Terrence et al. (1983), Nugent et al. (1986)). Abrupt 
withdrawal of baclofen has been reported to induce dyskinisias and psychosis 
(Kirubakaran et al. (1984)). Administration of baclofen to patients treated 
with anti-depressants can induce memory deficits (Sandyk and Gillman (1985)). 
The latter effect might be related to GABAB receptor upregulation (see 
paragraph 1. 3.) . Finally, baclofen has been reported to have beneficial 
effects in panic disorder (Pepplinkhuizen and Bruinvels (1978), Breslow et al. 
(1989). 
1.2.3. Modulation of activity of other neurotransmitter systems. 
A number of neurotransmitter systems are reported to be affected by 
activation of GABA receptors. The best documented interactions concern the 
effect of GABA receptor activation on release of GABA itself, glutamate and 
aspartate, dopamine, 5-HT and noradrenaline. 
A: GABA: It has been suggested that both GABAA and GABAB receptors are 
simultaneously involved in modulating the activity of the GABAergic system 
(Anderson & Mitchell (1985)). It is shown that GABAA autoreceptor activation 
inhibits release (Mitchell and Martin (1978), Brennan et al. (1981)) while 
reports on the effect of GABAB receptor activation are conflicting. It has 
been reported that GABAB receptor activation increases release of GABA (Kerwin 
& Pycock (1978), Roberts et al. (1978)), while other reports state that 
baclofen does not affect or even decreases GABA release (Anderson & Mitchell 
(1985), Potashner (1979), Collins et al. (1982), Johnston et al. (1980)', 
Pittaluga et al. (1987) Maurin (1988) and Bonanno et al. (1988)). Thus, it 
appears that the release of GABA can be modulated by activation of both GABAA 
and GABAB type receptors, depending on the brain region explored and 
experimental conditions used. 
B: Glutamate and aspartate: It has been shown that benzodiazepines inhibit 
release of glutamate and aspartate (Baba et al. (1983), Collins (1981)). 
However, this action might be GABA independent (Stone (1981)). A bicuculline-
sensitive GABA-induced inhibition of excitatory amino acid release is reported 
by Davies (1981) but a GABA-induced increase in glutamate release in 
cerebellar tissue is also reported (Levi et al. (1981)). In contrast, several 
reports exist on a baclofen-induced inhibition of glutamate and aspartate 
release (Potashner (1979), Fox et al. (1978), Davies (1981) and Collins et al. 
(1982)). 
C: Dopamine: A bicuculline- sensitive GABA-induced inhibition of 
dopaminergic neurons in the substantia nigra and ventral tegmental area is 
reported by Waszczak and Walters (1979) and Wolf et al. (1978). However, other 
studies indicate that systemic administration of muscimol (a selective GABAA 
agonist) increases firing of dopaminergic neurons in the pars compacta of the 
substantia nigra (Waszczak and Walters (1979)), and increases dopamine 
turnover in the caudate nucleus (Fuxe et al. (1979)). The effect of 
benzodiazepines om dopamine turnover are mostly described as inhibitory, while 
the interaction between the GABA and dopamine system is quite complex with 
region-dependent stimulatory and inhibitory effects (review: Taylor (1982)). 
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Baclofen inhibits substantia nigra cell firing (Olpe et al. (1977)) and 
decreases turnover in meso limbic dopamine neurons (Fuxe et al. (1975)). In 
vivo experiments -e.g. neuroleptic-induced hyperactivity and catalepsy, 
rotarod performance- indicate an effect of 1-baclofen on muscle hypotonia and 
sedation, while d-baclofen causes an impairment of the dopaminergic system 
(Kerwin et al. (1979). It is suggested by Delini-Stula (1977) that the effect 
of baclofen on conditioned avoidance behaviour and controversive turning is 
mediated by an inhibition of acetylcholine release, which on its turn 
decreases the inhibitory input on GABA-ergic neurones and thus increases the 
inhibitory influence on dopaminergic cells. Psychosis and dyskinesias have 
been reported after abrupt withdrawal of baclofen in humans (Kirubakaran et 
al. (1984)). Additional support for the suggestion of a link between baclofen 
and the dopaminergic system consists of a report by Mereu et al. (68), who 
suggest a supersensitivity of the dopamine autoreceptor after a single dose of 
baclofen. The same author tentatively suggested a similar mechanism for the 5-
HT and noradrenergic system. 
D: 5-HT: It was shown by Chase et al. (1970) that diazepam decreases the 
turnover of the 5-HT system. It was postulated by Wise et al. (1972) and Stein 
et al. (1973) that the anxiolytic action of benzodiazepines is caused by an 
inhibition of the 5-HT system. This effect of the benzodiazepines might be 
mediated via the GABAA-benzodiazepine receptor chloride channel complex since 
it has been shown that activation of GABA and benzodiazepine receptors exert 
an inhibitory effect on 5-HT neurones in vivo (Gallager (1978), Thiebot et al. 
(1980)) and in vitro (Balfour (1980)). On the other hand, some evidence exists 
that this effect of benzodiazepines might be GABAA-independent (Soubrie 
(1981)) and there are also reports which state that GABA has no effect on 5-HT 
transmission (Reubi et al. (1978), Starr (1979)). In addition, if present, it 
is not clear in what proportion the GABA-induced impairment of the 5-HT system 
is mediated via GABAA or via GABAB receptors. Baclofen has been shown to 
decrease the release of 5-HT from rat cortical tissue in vitro via activation 
of presynaptically located GABAB receptors (Schlicker et al. (1984), Gray and 
Green (1987) and Bowery et al. (1980)). Furthermore, activation of the GABAB 
receptor and of the 5-HTlA (auto)receptor have both been shown to increase 
potassium conductance in a shared potassium channel in the hippocampus and the 
raphe nuclei (Innis and Aghajanian (1987), Andrade et al. 1986)). Further 
evidence of GABAB receptor linkage with the 5-HT system will be described in 
the section of 5-HT receptor types. Some studies are worthwhile mentioning in 
the context of the relationship between GABA and 5-HT: It is reported by 
Handley and Singh (1985) that a certain type of 5-HTP-induced behaviour (head-
twitch) is enhanced by GABAA receptor activation (this was also shown in a 
GABAA independent way for the benzodiazepines (Moser and Redfern (1986)) but 
inhibited by GABAB activation. The GABAA and GABAB mediated effect on head-
twitch response was dependent on an intact noradrenergic system (Singh et al. 
(1986)). Two mechanisms were suggested to be responsible for this effect of 
baclofen: an inhibition of 5-HT release (Metz et al. (1985)), and/or a 
baclofen-induced postsynaptic antagonism which is modulated by the 
noradrenergic system (Singh et al. (1986)). 
E: Noradrenaline: It is reported that benzodiazepines impaired activity of 
the noradrenergic system, e.g. by means of inihibitory influence on the locus 
ceroeleus (Taylor and Laverty (1969), Grant et al. (1980)), while it is also 
shown that GABA enhances potassium-evoked release of noradrenaline from the 
rat occipital lobe (Langer and Arbilla (1979)). Fung and Fillenz (1983) 
reported that GABAA receptor activation or a low concentration of 
chlordiazepoxide enhance noradrenaline release from hippocampal tissue. The 
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reverse is shown for GABAB receptor activation and a high concentration of the 
benzodiazepine. From this results it has been suggested that chlordiazepoxide 
enhances the noradrenaline release via the GABAA-benzodiazepine receptor 
complex but decreases release in a high concentration. The latter effect is 
mimicked by alprazolam but not by diazepam, since only alprazolam inhibits the 
MHPG (3-methoxy-4-hydroxy-phenylethyleneglycol, a metabolite of noradrenaline) 
increase after yohimbine (Charney and Heninger · (198Sa). GABAB receptor 
activation inhibits the activity of the locus ceroeleus via an increase in 
potassium conductance at this region. Suzdak and Gianutsos (1985b) reported an 
increase and a decrease of noradrenaline release in rat cortex and hippocampus 
by GABAA and GABAB receptor activation respectively. The authors suggest a 
relationship between the noradrenaline system and the GABAB receptor at two 
levels: Firstly: since chronic administration of baclofen prevented a DSP4 (a 
neurotoxin that abolishes the presynaptic noadrenergic . neuron) -induced 
increase in Bmax of the ~-adrenoceptor, it was suggested that a relationship 
exists between the ~-adrenoceptor and the GABAB receptor at a postsynaptic 
level. Secondly: since the Bmax of the low affinity GABAB receptors decreases 
after DSP4 treatment (Suzdak and Gianutsos (1986a)), and the fact that a 
decrease in release of noradrenaline is observed, it was suggested that GABAB 
receptors are also located on the nerve terminal. On the other hand, it was 
reported by Bonanno and Raiteri (1987) that GABAB receptor activation did not 
affect noradrenaline release from rat hippocampus synaptosomes. The existence 
of an interaction between the noradrenergic system and the GABA system is 
supported by Suzdak and Gianutsos (1985b), who report that long-term treatment 
of baclofen and THIP (a selective GABAA agonist) decrease the Bmax of ~­
adrenoceptors in mouse cerebral cortex and hippocampus. A more precise 
description of the interaction between the ~-adrenoceptor and the GABAB 
receptor comes from Karbon and Enna (1983); Baclofen potentiates the 
norepinephrine-stimulated adenylate cyclase activity, presumably through a 
postsynaptic mechanism. 
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1.3. EFFECT OF LONG-TERM ADMINISTRATION OF ANTI-DEPRESSANTS ON 
GABAA, GABAB, BENZODIAZEPINE, 5-HT AND NORADRENERGIC 
RECEPTOR BINDING 
Since long-term administration of anti-depressants has anti-panic 
properties, it is of interest to review its effect on receptor binding of the 
neurotransmitters involved in anxiety. 
GABA: Pile and Lloyd (1984) described a GABAB receptor number increase in 
mouse frontal cortex after long-term treatment (18 days) with amitryptiline, 
desipramine, viloxazine, citalopram and a MAO inhibitor pargyline. The binding 
parameters of the GABAA receptor were unchanged. In contrast to these results, 
Suzdak and Gianutsos (1985a) reported that long-term (two week) treatment with 
the anti-depressants imipramine and nomifensine decreased Bmax of 1?>-adreno-
ceptors and GABAA receptors in the cortex and hippocampus of mice. The same 
group replicated the results of Pile and Lloyd (increased GABAB binding) and 
reported an increase of the baclofen-induced potentiation of cAMP production 
(Suzdak and Gianutsos (1986b)). Gray and Green (1987) reported that the GABAB-
induced inhibition of potassium-evoked 5-HT release from mouse frontal cortex 
is increased after chronic (14 days) treatment with amitryptiline, 
desipramine, mianserin or zimeldine. This was also shown after repeated 
electroconvulsive shock treatment (ECS). The same investigators found that the 
baclofen-induced hypothermia increased after treatment with the above-
mentioned anti-depressants (Gray et al. (1987)). However, Cross and Horton 
(1986) reported no change in GABAB receptor binding after long-term treatment 
with desipramine or zimeldine. 
The mechanism by which anti-depressants increase GABAB receptor binding is 
not clarified. It is observed that GABA levels increase and GABA uptake sites 
decrease during treatment with these compounds (Pile and Lloyd (1984)). It 
would implicate an unusual finding in pharmacology if the increase in GABAB 
receptors results from an enhanced receptor activation. However, there are 
precedents since GABAA receptors are reported to be increased after treatment 
with GABAA agonists (Beart et al. (1985)), and 5-HTz receptors are reported to 
decrease in number after treatment with antagonists (Leysen et al. (1986)). On 
the other hand, GABAB receptor binding is decreased after long-term 
administration of baclofen (Suzdak and Gianutsos (1986b)). This makes an 
activation-induced upregulation of receptor sites rather unlikely, unless GABA 
regulates GABAB receptor number in an opposite way as baclofen does. 
Benzodiazepine: Reports considering the effect of anti-depressants on 
benzodiazepine receptor binding are very mixed. Thus, an increase (Rozhanets 
et al. (1983)), decrease (Suranyi-Cadotte et al. (1985), Barbaccia et al. 
(1986)) and no change (Przegalinski et al. (1987)) has been reported. 
Adrenoceptots: It has been reported that long-term administration of anti-
depressants decreases a2-adrenoceptor binding (Crews and Smith (1978)), 1?>-
adrenoceptor binding (Sulser and Mobley (1981)), and norepinephrine-stimulated 
adenylate cyclase activity (Sulser (1979)). The a2-adrenoceptor ,agonist 
clonidine induces a sedation response and hypothermia which are both 
attenuated after repeated administration of ECS or anti-depressant drugs (Heal 
et al. (1981,1983), Von Voigtlander et al. (1978), Pile and Vitulani (1982)). 
5-HT: Long-term treatment with anti-depressants affects also 5-HT receptor 
binding (Maggi et al. (1981)). It was reported by Peroutka and Snyder (1980) 
that several anti-depressants downregulate 5-HT2 receptors. 5-HT2 receptor 
activation-induced head-twitch in the mouse was reported to be reduced after 
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long-term administration with anti-depressants (Friedman et al. (1983)), but 
ECS increased 5-HT2 binding in the rat (Kellar et al. (1981)) and a report 
exists of increased head-twitch after repeated ECS (Green et al. (1983)). The 
opposing effects of ECS and antidepressant drug treatment on binding and 
behaviour in mice were confirmed by Goodwin et al. (1984). In contrast, two 
reports state that 5-HTl binding sites are reduced after chronic 5-HT reuptake 
blockade (Wong and Bymaster (1981), Dumbrill-Ross and Tang (1983)). This is 
supported by the observation that repeated ECS and long-term (14 days) 
administration of zimeldine and desipramine attenuates the 8-0H-DPAT-induced 
hypothermia and 5-HT syndrom (Goodwin et al. (1987b)). Hypothermia is a 
presynaptically 5-HTlA induced effect, while 5-HT behaviour is a 
postsynaptically evoked effect (Goodwin et al. (1987a))). The attenuation of 
the 5-HT syndrom after anti-depressants was also reported by Stolz et al. 
(1983) but was only partly replicated by Lucki and Fraser (1982). The 
behavioural effects of 5-HTlB receptor activation after chronic administration 
was studied by Aulakh et al. (1987). It was reported that the locomotor and 
food intake suppressant effect of mCPP are enhanced after 21 days of treatment 
with imipramine. These results made the authors suggest that 5HT1B receptors 
become supersensitive after antidepressant pretreatment. However, it was 
reported by the same group that the MAO inhibitor clorgyline attenuates the 
above mentioned effects of mCPP (Cohen et al. (1983)). 
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1.4. THE 5-HT SYSTEM 
1.4.1. The neurotransmitter 5-HT. 
The cellbodies of 5-HT neurones are largely confined to the seven 
defined raphe nuclei of the rat brain stem. From these cell groups 
three major ascending projections to the forebrain are observed. They 
project to the a: caudate/putamen, b: substantia nigra and c: inter-
peduncular nucleus, ventral tegmentum, thalamus/hypothalamus, 
amygdala, cortex and hippocampus (Steinbusch and Nieuwenhuys (1983)). 
1.4.2. The 5-HT receptor types. 
Due to the development of selective 5-HT ligands, three types of 
5-HT receptors have been identified: 5-HTl, 5-HT2 and 5-HT3 
receptors. The 5-HTl receptor has been further subclassified into 5-
HTlA, 5-HTlB, 5-HTlc and 5-HTlD receptor types (Bradley et al. 
(1986), Heuring and Peroutka (1987)). The classification is based on 
a high or low receptor affinity for 5-HT and the various receptor 
ligands. 
5-HTlA~ 5-HTlA receptors are localized in the raphe nuclei and 
limbic terminal regions (hippocampus, septum) of the rat (Pazos and 
Palacios (1985), Glaser et al. (1985)). 8-hydroxy-2-(dl-n-
propylamino)tetralin) (8-0H-DPAT) is a selective agonist for this 
receptor type (Middlemiss and Fozard (1983)). Some caution has to be 
garded in interpreting 8-0H-DPAT effects as being mediated only via 
the 5-HTlA receptor, since an agonistic-like interaction with a2-
adrenoceptors is also described (Marsden (1989)). Other 5-HTlA 
ligands are buspirone, ipsapirone and gepirone. Buspirone is a 5-HTlA 
mixed agonist/antagonist which also blocks dopamine receptors while 
ipsapirone and gepirone are mixed agonistsjantagonists without 
dopamine blocking action. All three compounds are metabolized to 1-
pyrimidinilpiperazine, which blocks a2-adrenoceptors (Assie and 
Briley (1987), Giral et al. (1987)). No selective antagonist for the 
5-HTlA receptor is available, (cyano)pindolol and propranolol act as 
antagonists of 5-HTlA as well as 5-HTlB receptors (Middlemiss et al. 
(1977), Green et al. (1983)). 
It has been reported that activation of 5-HTlA receptors results 
in both augmentation and inhibition of adenylate cyclase activity. 
The direction of the induced effect might depend on the pre-existing 
state of the enzyme activity or on which subclass of 5-HTlA receptors 
is activated (Roth and Chuang (1987)). 5-HTlA receptors and GABAB 
receptors increase conductance in shared potassium channels via a 
pertussis toxin-sensitive G protein as has been shown in the 
hippocampus of the rat (Andrade et al. (1986)). In addition, Innis 
and Aghajanian (1987) reported that 5-HTlA and GABAB receptor 
activation inhibits 5-HT neuron activity in the rat dorsal raphe. 
This inhibition was also sensitive to pertussis toxin. 
Behavioural, or in vivo observable, effects of 5 -HT1A receptor 
activation are hypothermia and hyperphagia, mediated via activation 
of presynaptically localized 5-HTlA receptors (Goodwin et al. 
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(1987a), Dourish et al. (1986)). In addition, 5-HTlA receptor 
activation by 8-0H-DPAT induces signs of 5-HT behaviour, this appears 
to be mediated via postsynaptically localized 5-HTlA receptors 
(Tricklebank et al. (1984), Goodwin et al. (1987b)). The effects of 
5-HTlA agonists are anxiolytic-like in some, but not all animal 
models for anxiety (Riblet et al. (1982), Traber et al. (1984), Eison 
et al. (1986), Engel (1986) and McMillen et al. (1987), (see 
paragraph 1.6.)). 
The observed anxiolysis of 5-HTlA agonists in man is mostly 
ascribed to the decrease in 5-HT neuron firing rate after activation 
of somatodendri tic autoreceptors, however, it is possible that the 
postsynaptically mediated inhibitory action in the hippocampus also 
exerts an anxiolytic-like action (Marsden (1989). 
5-HTl~ This receptor type appears to be present in rat and mouse 
brain only (Heuring et al. (1986)). The highest densities of 5-HTlB 
receptors are found in the caudate, superior colliculus, lateral 
geniculate, subiculum, globus pallidus and substantia nigra (Pazos 
and Palacios (1985)). The most selective 5-HTlB agonist is 5-methoxy-
3 ( 1, 2, 3, 6- tetrahydro-4-pyridinyl) lH indole succinate (RU24969). 
However, this compound and also 1- [ 3- (Trifluoromethyl)-
phenyl]piperazine (TFMPP) and 1-(3-chloro-phenyl)piperazine (mCPP) 
are not completely selective for 5-HTlB receptors since all three 
drugs have also some affinity for the 5-HTlA receptor (Peroutka 
(1986)). 
It is not known which second messenger is linked to the 5-HTlB 
receptor. The functional correlate of the 5-HTlB receptor appears to 
be the 5-HT terminal autoreceptor and a postsynaptic receptor. An 
interaction between the 5-HT reuptake site and the 5-HTlB receptor is 
also described since 5 -HT reuptake inhibitors acutely reduce the 
efficacy and potency of 5-HTlB agonists (Langer (1982)). 
The effects of postsynaptic activation (e.g. anorexia, 
hyperlocomotion) prevail in vivo after administration of 5-HTlB 
agonists, it appears that there are no drugs available which 
selectively activate pre- or postsynaptic 5-HTlB receptors (Kennett 
et al. (1987)). 
5-HTlc and 5-HT2_;_ The 5-HTlc receptor has been localized in the 
choroid plexus, frontal cortex and hippocampus (Pazos et al. (1984), 
Pazos and Palacios (1985)). The 5-HT2 receptors are mainly found in 
the IIIth and IVth layer of the cerebral cortex, claustrum, olfactory 
tubercle, caudate nucleus and nucleus accumbens of human and rat 
brain (Luabeya et al. (1984), Leysen et al. (1982), Hoyer et al. 
(1986)). Selective ligands for the 5-HT1c receptor are not available. 
Mianserine, mesulergine and metergoline are antagonists with a high 
affinity for the 5-HTlc receptor. There is a considerable overlap of 
ligand-binding profile with the 5-HT2 receptor. Thus it is shown that 
5-HT2 antagonists like ritanserin, cyproheptadine and pizotifen are 
also 5-HTlc blockers (Hoyer (1988)). The compound 1-(2,5-dimethoxy-4-
iodophenyl)-2-aminopropane (DO!) is an example of a quite selective 
5-HT2 agonist (Glennon et al. (1986)). 
5-HTlc and 5-HTz receptor activation leads to stimulation of 
phospholipase C and to the breakdown of inositolphospholipids (Conn 
et al. (1986)). This may on its turn affect ion channel activity, 
e.g. the calcium activated potassium channels (VanderMaelen and 
Aghajanian (1982)). 
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The 5-HTlc receptors in the choroid plexus may be involved in the 
composition and volume of the cerebro-spinal fluid (Moskowitz et al. 
(1979)). The 5-HT2 receptor displays a high affinity for a number of 
neuroleptics (Peroutka and Snyder (1979)). Effects of 5-HT2 receptor 
activation are for instance head twitching in mice and wet-dog shakes 
in rats (Leysen et al. (1984)). In man, 5-HT2 receptor stimulation 
appears to play a role in the effects of hallucinogenic compounds 
like LSD (Glennon et al. (1984)). In addition, it is postulated that 
5-HT2 blockade exerts an improving effects in dysthymia, aggression 
and anxiety. 
5-HTl~ This binding site has been identified recently. Regional 
studies in bovine brain indicate that the site exists in all regions 
of the brain but most densely in the basal ganglia. Nothing is known 
about the existence of a second messenger or a functional correlate 
linked to this site. No selective ligand is available, but 
tryptamines, ergotamines, RU24969 and yohimbine display high affinity 
for the 5-HTlD site (Heuring and Peroutka (1987)). 
5-HT3_;_ The 5-HT3 receptor has initially been identified in the 
peripheral nervous system (Bradley et al. (1986)). However, binding 
sites are now shown in membrane preparations of entorhinal cortex and 
cortical and limbic regions (Kilpatrick et al. (1988)). It is not 
clear whether these receptors are localized pre- or postsynaptic to 
the neuron cell body. Several selective 5-HT3 ligands are available: 
2-methyl-5-HT (agonist), GR38032F, ICS 205-930 and MDL 72222 
(antagonists). It is speculated that 5-HT3 antagonists may have a 
beneficial effect in migraine (Loisy et al. (1985)), anxiety and 
psychosis (Tyers et al. (1987)). 
For reviews, see Fozard (1987), Roth and Chuang (1987), Heuring 
and Peroutka (1987) and Conn and Sanders-Bush (1987). 
1.4.3. 5-HT reuptake inhibitors. 
On the way to find equipotent but better tolerated anti-
depressants, and to find drugs with more specific and selective 
activity, the group of selective 5-HT reuptake inhibitors has been 
developed. Among the best known and clinically used are fluvoxamine, 
fluoxetine, trazodone and clomipramine. The binding sites for these 
compounds are assumed to be localized presynaptically in the raphe 
nuclei and on the 5-HT nerve terminals of the projection sites 
(review: Chesselet (1984)). Fluvoxamine belongs to the most selective 
drugs within this group, since this compound has not only no effect 
on reuptake of noradrenaline or dopamine, but has also no affinity 
for al, a2, R>l, dopamine2, histamine1, muscarinic, 5-HTl and 5-HT2 
receptors (Benfield and Ward (1986)). 
It has been reported that selective 5-HT reuptake inhibitors have 
not only a beneficial effect on depression and suicidal ideation, but 
also on panic disorder with or without agoraphobia, obsessive 
compulsive disorder, posttraumatic stress disorder, obesity, alcohol 
abuse, impulsivety and aggression (Van der Kolk (1987), Westenberg 
and den Boer (1988), Linnoila (1988)). · 
The mechanism behind the therapeutic action of selective 5-HT 
reuptake inhibitors is not fully clarified. For instance, several 
12 
hypotheses concerning the anti-panic efficay of anti-depressants 
exist: Desensitization of postsynaptic 5HT1 receptors (Den Boer 
(1988)), an enhanced GABA(B) receptor activation (Breslow et al. 
(1989)), or downregulation of adrenoceptor sites (Charney and 
Heninger (1985b)). The latter effect has also been observed with the 
selective 5-HT reuptake inhibitor fluvoxamine (Racagni (1984)). 
It is shown that selective 5-HT reuptake inhibitors have 
different effects on the 5-HT system after acute or chronic 
administration. The functional consequences after acute 
administration are generally believed to be a facilitation of 
serotonin neurotransmission (Schipper and Berkelmans (1988)). 
However, there are some conflicting data on this matter: 
investigations on a neurochemical level have shown that 5-HT 
turnover, synthesis rate and firing rate are decreased after a 
selective 5-HT reuptake inhibitor (Schipper and Berkelmans (1988), 
Dresse and Scuvee-Moreau (1984)). It has to be noted however, that 
these decreases might be caused by a feed-back mechanism induced via 
postsynaptic 5-HT activation at the projection sites. Thus, 
behavioural studies and electro-fysiological studies indicate a 
potentiation of 5-HTP effects (Claassen et al. (1977)) and 
postsynaptic fysiologic responses (de Montigny et al. (1984)). 
Besides the presynaptic 5-HTlA receptor and the postsynaptic 5-HTl 
and 5 -HT2 desensitisation (receptor binding experiments and 
behavioural studies, see paragraph 1.3.), Chaput et al. (1988) 
described in an electrophysiological study a desensitization of cell 
body and terminal autoreceptors. 
1.4.4. Effect of 5-HT modulating drugs on human anxiety. 
It has been hypothesized by the group of Wise and Stein that the 
anxiolytic effect of the benzodiazepines is mediated via an 
impairment of the 5-HT system function (Wise et al. (1972), Stein et 
al. (1973)). As stated already in paragraph 1. 2. 3. , this effect of 
the benzodiazepines might be mediated on its turn via the 
GABAA/benzodiazepine receptor chloride channel complex. 
Benzodiazepines are often prescribed for generalized anxiety 
disorder. This is consistent with the fact that it has been shown 
that 5HT1A autoreceptor agonists like buspirone, gepirone and 
ipsapirone (Ortiz et al. (1987), Csanalosi et al. (1987), Traber and 
Glaser (1987)), have a similar beneficial effect in this anxiety 
disorder. Buspirone has some beneficial effect on anticipatory 
anxiety in panic disorder, it has no effect on panic attacks 
(Robinson et al. (1989)). The anxiolytic effect of 5-HTlA receptor 
agonists might be due to activation of the presynaptic 
(somatodendritic) autoreceptor (see also paragraph 1.4.2.), andjor to 
activation of the postsynaptic 5HT1A receptor in the hippocampus, 
which inhibits firing at that locus (Andrade et al. (1986), Marsden 
(1989)). It has been claimed that 5-HTz receptor blockade has 
be~eficial effects in generalized anxiety disorder (Ceulemans et al. 
(1985), Bressa et al. (1987)), but it has no effect on any of the 
components of panic disorder (Den Boer (1988). The effect of 5-HT 
reuptake inhibitors on anxiety is mentioned in paragraph 1.4.3. The 
most recent claim is the putative anxiolytic effect of 5-HT3 
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antagonists (e.g. GR38032F) by Tyers et al. (1987). It is not known 
yet what anxiety syndromes are affected by the latter compounds. 
The hypothesis that the 5-HT system has an important role in 
panic disorder is supported by a number of observations: The 
treatment of patients with 5-HTP (in combination with peripheral 
decarboxylase inhibition) exerts an anti-panic effect (Kahn and 
Westenberg (1985), Kahn et al. (1987)), it was noted that anxiety 
was slightly elevated in the first treatment week. The latter effect 
was also noted by Den Boer, using fluvoxamine (1988). In addition, 
mCPP, a 5-HT1 receptor agonist, causes anxiety in panic disorder 
patients (Charney et al. (1987), Kahn et al. (1988)). The latter two 
groups reported contrasting data on the effect of mCPP on healthy 
subjects. Fenfluramine, a 5-HT releaser, has been reported to 
increase anxiety selectively in panic disorder patients, as well as 
inducing a greater cortisol and prolactine response in patients than 
in controls (Targum and Marshall (1989)). It has been reported that 
selective 5-HT reuptake inhibitors have anti-panic efficacy (Evans et 
al. (1986), Kahn et al. (1987), Den Boer (1988)). Several challenge 
tests are performed in order to further investigate the 5-HT system 
involvement in panic disorder. Kahn et a1. (1988) reported an 
augmented cortisol release after mCPP administration in panic 
disorder patients, and suggested a 5-HT1 receptor supersensitivity in 
this group of patients. Taken together, these data suggest an 
important role of the 5-HT system in anxiety and in panic disorder. 
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1. 5. OTHER NEUROTRANSMITTER SYSTEMS AND ANXIETY 
1.5.1. Noradrenergic system. 
There is not much doubt that the noradrenergic system is in some way 
involved in the pathogenesis of anxiety (review: Redmond and Huang (1979)). 
There is evidence that adrenoceptor ligands such as adrenaline, noradrenaline, 
yohimbine (a2 autoreceptor antagonist) and isoproterenol (~-adrenoceptor 
agonist) induce anxiety- and panic-like symptoms in man and animals (Garfield 
et al. (1967), Charney and Heninger (1982), Frohlich et al. (1969)). In 
addition, some indication exists that clonidine (a2 autoreceptor agonist) and 
propranolol (~-adrenoceptor antagonist) have a weak anxiolytic effect (Hoehn-
Saric (1982), Noyes et al. (1984)). Furthermore, it is postulated that the 
downregulation of a2- and ~-adrenoceptor number and function are responsible 
for the anxiolytic effects of anti-depressants (Charney and Heninger (1985b)). 
The specific involvement of the noradrenergic system in the symptoms of 
patients suffering from panic disorder is supported by a number of data: 
Yohimbine elecits panic attacks in 50 % of panic disorder and agoraphobic 
patients, while this was seldom seen in control groups. MHPG, cortisol and 
blood pressure increases after administration of yohimbine were larger in 
panic disorder patients than in healthy controls. Also, the decrease of MHPG 
and blood pressure, and the attenuation of anxiety is greater in panic 
disorder patients than in controls after clonidine administration (Charney and 
Heninger (1986), Nutt (1989)). In contrast to these increased effects of 
clonidine, other effects of a2-adrenoceptor activation like sedation and 
growth hormone release are smaller in patients than in controls. This suggests 
a regional difference of a2-adrenoceptor sensitivity alterations in panic 
disorder (Nutt (1989)). Panic attacks are reported after isoproterenol (Pohl 
et al. (1985)), while, in addition, a chronic general increase in sympathetic 
tone has been found in patients suffering from panic disorder (Villacres et 
al. (1987)). Inhibition of the reuptake of noradrenaline induces an a2-
adrenoceptor subsensitivity, this might be related to the anti-panic effects 
of these drugs. However, it has been reported that imipramine decreased the 
number of the panic attacks of patients while the yohimbine-induced changes 
(MHPG, blood pressure and anxiety) in the same patients were unaltered 
(review: Heninger (1988)). Clonidine has anxiety reducing properties in panic 
disorder, but a fast tolerance (approximately 3 days) develops, and its 
effects differs considerably per patient (Uhde et al. (1989)). Two groups 
reported that propranolol has a modest effect on panic anxiety, but two other 
groups reported that the drug was not effective (review: Munjack et al. 
(1989)). 
When the role of the noradrenergic (or 5-HT) system in anxiety is 
discussed, it must be realized that the noradrenergic system is functionally 
linked with the 5-HT system, e.g. the locus coeruleus receives projections 
from the nucleus raphe and vice versa (Descarrier and Leger (1978), Leger et 
al. (1979), Fuxe et al. (1978)). An increased activity of the raphe nuclei has 
an inhibitory effect on the locus coeruleus, but an increased activity of the 
latter increases the firing rate of neurons in the raphe nuclei (Segal (1979), 
Aghajanian (1980)). Furthermore, the anti-depressant-induced downregulation of 
~-adrenoceptors in animal studies requires an intact 5-HT system (Brunelle et 
al. (1982)). In addition, the existence of functional a2-adrenoceptors on 5-HT 
terminals has been reported (Feuerstein et al. (1985)), several ~-adrenoceptor 
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antagonists are effective 5-HTl blockers 
Costain and Green (1978)), and in addition 
yohimbine has a high affinity to 5-HTlD 
Peroutka (1987). 
(Green and Graham-Smith (1976), 
to its a2-adrenoceptor blockade, 
recognition sites (Heuring and 
Taken together, this suggests that it is impossible to postulate a specific 
and selective role of the noradrenergic or serotonergic system in the 
pathofysiology of panic disorder. 
1.5.2. Dopaminergic system. 
Dopamine receptor blockers may be prescribed as anxiolytics in borderline 
and prepsychotic patients (Brinkley et al. (1979)). They may also be effective 
in benzodiazepine resistant anxiety (Rickels (1978)). On the other hand, the 
dopamine receptor agonist apomorphine has also been prescribed as an 
anxiolytic (Medan (1979)). 
1.5.3. Cholinergic system. glutaminergic system and ethanol. 
Belladonna (atropine) was used as an anti-anxiety agent before the 
barbiturates were introduced in 1903 (Harvey (1975)). In addition to atropine, 
the muscarinic receptor blocker scopolamine has been used as an anxiolytic 
lateron (Rickels (1978)). However, no large studies investigating specific 
anxiolytic effects of anti-cholinergics have been performed. 
It is postulated recently that excitatory amino acid (glutamate, aspartate) 
receptor antagonists may have anxiolytic activity since it has been shown that 
these compounds are active in several animal models for anxiety (Stephens et 
al. (1986), Bennett and Amrick (1986), Clineschmidt et al. (1982) and Dunn et 
al. (1989)). 
Ethanol was and is still used as a self-prescribed anxiolytic; its action 
is probably mediated by the GABAAjbenzodiazepine receptor chloride channel 
complex (Burch and Ticku (1980)). 
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1. 6. ANIMAL MODELS FOR ANXIETY 
Numerous behavioural models have been developed in order to be used as a 
screening instrument for the detection of anxiolytic drugs. Animal models for 
anxiety have to meet to at least a number of criteria as specified recently by 
Shephard (1984): 1/ Specificity: Anxiolytic effects in an animal model should 
be induced by more than one compound from one class of drugs with similar 
pharmacological actions (e.g. benzodiazepines, GABA agonists, barbiturates, 5-
HT antagonists etc). 2/ Sensitivity: The model is expected to be sensitive for 
a low dose of a benzodiazepine. 3/ Correlation with clinical potency: There 
ought to be a correlation between clinical potency of drugs and drug potency 
in the animal model. 4/ Absence of tolerance: Anxiolytic action of a drug 
should still be present after a few days of daily administration of the drug. 
5/ Validity: The action of drugs in a model should not be based on another 
motivational system like feeding or anti-nociception. These criteria receive 
some criticism since the present tests rely heavily on the effects of 
benzodiazepines. It is conceivable that the present models are therefore more 
or less "suited" to the anxiolytic profile of the benzodiazepines (Abbott 
(1987)), which might be incorrect since the latter compounds are not effective 
in all forms of anxiety in man. 
Most animal models for anxiety make use of punished operant behaviour (e.g. 
Geller-Seifter test, punished drinking (Vogel's test)), neophobia (shock prod 
burying, marble burying), social interaction and innate behaviour (e.g. 
aversion for open field, brightly illuminated areas). Some presently used 
models and the models used in the experiments described in chapter II to V 
(conflict behaviour and extinction of conflict behaviour) are discussed below. 
1.6.1. Conflict models. 
The Geller-Seifter conflict test (Geller and Seifter (1960)) is a procedure 
in which food-deprived rats follow a multiple schedule in which periods of 
partial reinforcement (random interval (RI) schedule) alternate with periods 
in which every response is rewarded with food (fixed ratio (FR) 1 schedule), 
but in which the latter is also accompanied by electric shock. The desired 
degree of behavioural suppression can be obtained by appropiate adjustment of 
shock severity. It is shown that barbiturates, meprobamate and benzodiazepines 
enhance the rate of punished responding (FR 1 schedule) (Geller and Seifter 
(1960), Geller et al. (1962), Geller (1964)). This effect is attributed to an 
anxiolytic effect of the drugs since this effect would resolve the "conflict" 
between fear for the foot-shock on one hand, and desire for feeding on the 
other hand. The inhibition of conflict behaviour is also called "anti-conflict 
effect". The RI schedule is designed as a control for adverse reactions, like 
sedation, ataxia, muscle relaxation etc, and to maintain "ongoing" behaviour. 
In a part of the experiments described in chapter II, III and IV, the Geller-
Seifter conflict test was used with some adjustments (see method sections). 
The Geller-Seifter test receives criticism on the point that drugs may exert a 
seemingly anti-conflict effect via an increase in other drives (e.g. feeding, 
anti-nociception, general rate-enhancing effects), the time-consuming aspect 
of the procedure, and the for the animal unnatural behaviour (in comparison 
with social interaction for instance). Several drugs that impair activity of 
the 5-HT system (e.g. PCPA, 5-HTJ.A agonists, 5-HT2 antagonists) have been 
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reported to exert an anti-conflict effect in the conflict procedures, but the 
effects are weak in comparison with the benzodiazepines and a number of 
negative results are also reported. 5-HT reuptake inhibitors (acute 
administration) were inactive or even enhanced shock-induced suppression. 
(Reviews: Chopin and Briley (1987), Broekkamp et al. (1989)). 
Vogel's test: This conflict test procedure uses water deprived animals, of 
which punished (electric shock) drinking is monitored. No training is 
necessary in this procedure. Benzodiazepines exert an anti-conflict effect 
since they enhance punished drinking (Vogel et al. (1971)). Criticism on this 
procedure is mainly centered around effects of drugs on drinking per se and 
anti-nociception. The missing of monitoring the motor performance during this 
test may also be an uncertain factor in this procedure. The effect of drugs 
which modulate the 5-HT system are largely the same in Vogel's test and in the 
Geller-Seifter conflict test. 
1.6.2. Neophobia. 
Procedures based on the fear for novelty were initially called conflict 
tests, since it was felt that animals were in conflict between their desire to 
feed themselves and fear for the novel environment in which they were placed 
or to novel food which was presented. Administration of benzodiazepines 
enhances feeding in these procedures (Poschel (1971)). In analogy with the 
above-mentioned tests, also here criticism is focussed on a possible drug-
induced enhancement of food intake. 
Other tests which belong at least partly in this group are the tests using 
the placement of unfamiliar objects in a novel environment of the rats and 
observe behaviour afterwards (e.g. defensive burying test, shock probe 
conflict test (Broekkamp et al. (1986), Meert and Colpaert (1986a)). Marble 
burying is decreased after administration of benzodiazepines and 5-HT reuptake 
inhibitors, but not affected by 5-HT antagonists, 5-HTlA agonists or a 5-HTlB 
agonist (Broekkamp et al. (1986,1989)). In the shock probe conflict procedure 
rats are placed in an unfamiliar environment where a shock probe is present. 
Exploration of the probe is enhanced after administration of benzodiazepines. 
A number of 5-HT antagonists and 8-0H-DPAT are weakly active, ipsapirone and 
buspirone have no effect (Meert and Colpaert (1986a, 1986b)). 
1.6.3. Social interaction. 
This paradigm assesses interactions between the test animal and an 
undrugged animal in a novel environment (File and Hyde (1978)). Like 
neophobia, it utilizes the aversion of rats to novelty as an inhibitory 
behavioural influence. It is proposed that this test is a better reflection of 
clinical anxiety since it does not use predictable aversive experience (i.e. 
there is more "uncertainty" in the rat than in the conflict models). The use 
of t;he model does not need training and starvation. Social interaction is 
increased by benzodiazepines (File and Hyde (1978)). The reports on 5-HT 
modulating drugs and social interaction are mixed: Methysergide, metergoline, 
clomipramine are not active (File (1981, 1985)). Buspirone, ipsapirone, PCPA 
and GR38032F are reported to be active (File and Hyde (1977), Schuurmans and 
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Spencer (1987), Gardner (1985), Jones et al. (1987)). A negative result on 
buspirone is reported by File (1985). 
1.6.4. Other animal models for anxiety. 
Four Plate: This test is based on the innate behaviour of an animal to explore 
a novel environment. Crossings from one part to the other part of a test floor 
are foot shock punished. Benzodiazepines, fluvoxamine and ipsapirone enhance 
crossings, but PCPA, methysergide, buspirone and clomipramine do not (Boissier 
et al. (1968), Aron et al. (1971), Molewijk and Vander Heijden (1988)). 
Elevated plus maze: The elevated plus maze test is b'ased on the fact that 
rats tend to avoid exposure to an elevated and open maze alley. This tendency 
is opposed by the innate drive of the animal to explore its environment. The 
animals may choose between an open and a closed alley, the increase in 
percentage of open arm entries provides a measure for anxiolytic activity of 
drugs like the benzodiazepines (Pellow et al. (1985)). Metergoline, 
ketanserine, ritanserine have anxiolytic activity, but 5-HTlA agonists, RU 
24969 and quipazine were not active or seem to act as anxiogenic compounds in 
this test. Propranolol, fenfluramine, paroxetine and indalpine were reported 
to be anxiogenic (Pellow et al. (1987), Critchley and Handley (1986), Handley 
and Mithani (1984), Chopin and Briley (1987)). 
One trial passive avoidance: This test depends on a conflict between the rat's 
aversions for a brightly illuminated area on one hand, and a dark compartment 
in which the animal received a foot-shock 24 hours before the test on the 
other hand (Ader et al. 1972)). Benzodiazepines shorten the latency for 
reentry in the dark compartment while also the anxiolytic ipsapirone decreases 
passive avoidance (Gray (1982), Traber et al. (1984)). 
One should be careful with interpreting the effects of anxiolytic drugs in 
this procedure, since effects . on memory and locomotion might affect the 
results of the test. In fact, this paradigm is used as a measure for drug-
induced changes in consolidation, retention and retrieval of memory processes. 
Research on memory retrieval revealed that pirenperone, ketanserin, mianserin, 
methysergide, metergoline, alaproclate and zimeldine increased latency in a 
passive avoidance task procedure (Altman and Normile (1986), Altman et al. 
(1984)). It is conceivable that the latter effect might be explained by an 
enhanced retrieval of memory and/or an anxiogenic effect per se. 
Aversive brain stimulation: Electrical stimulation of the dorsal central grey 
area holds an aversive effect for the rat. The aversive threshold can be 
determined by measuring the current at which stimulation induces flight 
behaviour. This threshold is increased after the administration of GABAA 
agonists or benzodiazepines (Audi and Graeff (1984), Brandao et al. (1982)). 
5-HT, clomipramine and 5-HTP have an anti-aversive action (Schutz et al. 
(1985), Kiser et al. (1978)). The anti-aversive action of 5-HT was blocked by 
metergoline or ketanserin (Schutz et al. (1985)). Pirenperone and ketanserine 
were found to have an anti-aversive action, 5-HT3 blockade did not show any 
efficacy, metergoline and mianserine facilitate aversive stimulation (Jenck et 
al. (1989a, 1989b)) . 
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1.6.5. Short comment on extinction of conflict behaviour. 
The adjusted Geller-Seifter conflict test without foot-shock punishment in 
the test situation was used as the procedure for extinction of conflict 
behaviour (see method sections). It has been shown by Cook and Davidson (1973) 
that FR 1 responding increases after omitting foot shock in the Geller-Seifter 
test. In untreated rats it takes three days before the original level of 
responses has been reached again. This process of returning to the pre-
existing level of FR 1 responding may be explained as an "extinction of 
aversive experience", or as "extinction of conflict behaviour". This model is 
based on the tentative hypothesis that extinction of conflict behaviour of the 
rat may be close to the anxiety experienced by man after the occurrance of an 
aversive event. Therefore, extinction of conflict behaviour might be a model 
with predictive value for drugs which affect phobic and/or anticipatory 
anxiety symptoms in man (see paragraph 1.7.). 
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1.7. PANIC DISORDER 
Panic disorder is an anxiety disorder that generally consists of two 
components: panic attacks and anticipatory anxiety. A case-history nearly 
always starts with a spontaneous panic attack in persons who feel quite well, 
although there are indications that an imminent threat of separation (e. g. 
from closely-related members of the family) triggers the first attack(s). The 
anticipatory anxiety is characterized by the fear of having (another) panic 
attack. Along with this, the patients develop a general chronic increase in 
the level of anxiety, which has the characteristics of a generalized anxiety 
disorder (Uhde et al. (1985)). In addition, phobic avoidance (agoraphobia), 
which can be described as a fear for particular places at which no help will 
be available in case of a sudden incapacitation, often accompanies the panic 
disorder. The exact etiology and pathogenesis of an attack has not been 
clarified yet. There seems to be a genetic predisposition for developing panic 
disorder (Crowe et al. (1980), Torgersen (1983)). In addition, several methods 
to provoke panic-like anxiety have been described, e. g. lactate infusion 
(Pitts and McClure (1967)), caffeine (Boulenger et al. (1984)), yohimbine or 
isoproterenol administration (Charney and Heninger (1985), Rainey et al. 
(1984)), mCPP or other compounds that increase postsynaptic 5-HT function 
(Kahn and Westenberg (1985), Kahn et al. (1988)), and C02 administration (Van 
den Hout and Griez (1984)). These observations formed the basis for several 
hypotheses about the pathogenesis of panic disorder, of which the serotonergic 
and noradrenergic theory seem the most attractive ones (see also discussion 
and appendix). 
It is postulated by Klein (1964) that patients couple the environment in 
which the panic attacks occurred to the cause of the panic attack itself. In 
this way, phobic avoidance behaviour develops secondary to the panic attacks 
and might be considered as a learned response to the aversive event which is 
represented by the panic attack. This concept is supported by a large number 
of investigations but is still a matter of contradiction since several reports 
seem difficult to fit in with this hypothesis: Firstly, the existence of a 
very small group of patients with phobic avoidance behaviour without 
concomitant panic attacks. It is possible however that these patients have a 
very adequate phobic avoidance and/or still show phobic avoidance after a long 
forgotten panic attack (Marks (1987)). Secondly: phobic behaviour (school-
phobia and/or separation anxiety) in children shows a remarkable similarity 
with agoraphobia of adults (Perugi et al. (1988)). Although sometimes present 
in adolescents, panic attacks are generally absent in children. However, it is 
interesting to note that schoolphobic children often develop panic disorder at 
an older age and/or have parents with panic disorder. Thirdly: Phobic 
avoidance, generalized anxiety and hypochondriacal ideas are reported to be 
present before the onset of panic attacks (Fava et al. (1988). This is 
supported by a study of Thompson et al. (1989), who report an earlier onset of 
agoraphobia (low teens) than panic disorder (about 20). 
Taken together, the present reports make it doubtful that phobic avoidance 
and general anxiety disorder occurring in patients suffering from panic 
disorder, are solely the result of panic attacks. It is not unlikely that at 
least a subgroup of the patients shows avoidance behaviour without a causal 
relationship with the (preceding) panic attacks. 
As stated before (par. 1.4.4. and 1.5.1.), theories concerning the 
neurochemical mechanism behind the pathofysiology of panic disorder mainly 
concern the function of the 5-HT system and/or the noradrenergic system in 
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CHAPTER II 
GABA-B RECEPTOR ACTIVATION AND CONFLICT BEHAVIOUR. 
C.E.J. Ketelaars, E.L. Bollen, H. Rigter and J. Bruinvels. 
published in Life Sciences 42:933-942, 1988 
Summary 
Baclofen and oxazepam enhance extinction of conflict behaviour in the 
Geller-Seifter test while baclofen and diazepam release punished behaviour in 
Vogel's conflict test. In order to investigate the possibility that the effect 
of the selective GABA-B receptor agonist baclofen is mediated indirectly via 
the GABA-Ajbenzodiazepine receptor complex, the effect of pretreatment of rats 
with baclofen on [3H]-diazepam binding to washed and unwashed cortical and 
cerebellar membranes of rats has been studied. Baclofen pretreatment increased 
Bmax in washed cerebellar membranes when bicuculline was present in the 
incubation mixture. No effect was seen in cortical membranes. The present 
results render it unlikely that the effect of baclofen on extinction of 
conflict behaviour and punished drinking is mediated via the 
GABA-A/benzodiazepine receptor complex. 
Introduction 
The receptors for T-arninobutyric acid (GABA) and the benzodiazepines in the 
central nervous system are closely associated (1,2,3,4). The extent in which 
the anxiolytic, anti-convulsant, sedative and muscle relaxant effects of the 
benzodiazepines are mediated via the GABA-ergic system has been studied 
extensively. The results of these investigations are more equivocal concerning 
anxiolysis than for the other effects (5,6,7,8). 
GABA receptors in rat brain are subdivided according to their sensitivity to 
the GABA receptor antagonist bicuculline and the GABA-analog baclofen 
(~·(p-chlorophenyl)-GABA). GABA-A receptors are sensitive to bicuculline and 
not to baclofen, while GABA-B receptors are sensitive to baclofen and not to 
bicuculline (9, 10). Although evidence exists that the GABA-benzodiazepine 
receptor interaction in vitro applies only to the GABA-A receptor and not to 
the GABA-B receptor (11,12), it is still conceivable that activation of the 
GABA-B receptor in vivo may affect GABA-benzodiazepine receptor interaction. 
Thus it has been reported that GABA-B receptor activation increases release of 
GABA (13,14), which may subsequently increase the affinity of benzodiazepine 
receptors (1,2). Other reports however state that baclofen does not affect or 
even decreases GABA release (15-18). Furthermore, it has been reported that 
GABA-B receptor activation in vivo increased benzodiazepine receptor binding 
in vitro (19,20). 
On the behavioural level, baclofen predominantly has muscle relaxant, sedative 
and anti-convulsant properties (21,22). Baclofen as well as the 
benzodiazepines have been shown to interfere with aquisition of a conditioned 
emotional response (23,24). In contrast with the benzodiazepines, baclofen has 
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no anti-conflict effect in the Geller-Seifter test (25). However, the results 
of only one type of test should not be taken as decisive evidence. It is also 
possible to study effects of drugs on the behaviour of rats in the Geller-
Seifter test in the absence of foot shock (26). So far, effects of 
benzodiazepines and other drugs on the extinction of conflict behaviour have 
not been studied. 
In the present studies it was shown that baclofen and a benzodiazepine 
increased extinction of conflict behaviour and had an anti-conflict effect in 
Vogel's conflict test. 
To establish whether baclofen exerts its action via the GABA-A/benzodiazepine 
receptor complex, the effect of baclofen on benzodiazepine receptor binding 
was studied. 
Methods 
Behavioural studies. 
In order to study extinction of conflict behaviour, the Geller-Seifter test 
(27) was used with some small modifications. The effects of baclofen and 
oxazepam were measured separately in two groups of 12 rats. 
Procedure: After being deprived of water for 16 hours, male Wistar rats 
(starting weight: 80 g, training was completed at 300 ± 50 g) were placed in 
an experimental chamber measuring 20 x 20 x 20 em, containing a response 
lever, milk delivery apparatus, an electrifiable grid floor and a stimulus 
light. The rats were trained to press a lever in order to obtain milk and were 
subsequently trained once a day for a duration of 42 minutes. In these 
training periods, two schedules were used in alternation. In 6 periods of 5 
minutes a 5 % chance of reward was offered, resulting in a random interval 
schedule. The 5 % chance intervals were generated with the aid of a random 
generator based on electric noise. In 6 periods of 2 minutes a fixed ratio 1 
(FR 1) schedule was used in which a steady light signal served as a 
discriminative stimulus. After stabilization of performance, response-
contingent foot shock was given during the FR 1 periods. The shock level was 
individually adjusted until cumulative lever pressings during the FR 1 periods 
were below 5 per 12 minutes, which is about 5 % of the number of lever 
pressings before foot shock was applied. Extinction of conflict behaviour was 
measured on test days using the same set-up, except that foot shock was turned 
off. Between testdays training continued, and shock levels were adjusted when 
the animals took more than 5 shocks per 12 minutes. After 20 training 
sessions, spontaneous extinction was virtually non-existent in saline-injected 
rats ; i.e. these animals responded with an average of 2 to 5 pressings per 12 
minutes. Drug effects on extinction of conflict behaviour were measured each 
time after at least 2 days of training in order to achieve a stable "base 
line" of conflict behaviour. Oxazepam was used in doses that did not release 
punished behaviour in the presence of foot shock. Drugs were administered once 
a week to allow for a sufficiently long wash out period. 
In order to study punished licking, Vogel's conflict test was used (28) with 
some modifications, as described by Wren et al. (29). Male Wistar rats 
(170-250 g) were only allowed to drink for 45 min per day 2 hours after the 
test. After two days of acclimatization sessions in which the rats accustom to 
drinking from the waterspout, the third day a shock (1 rnA) was delivered 
through the spout every 20th lick. The number of licks per 15 min were 
counted. Baclofen was tested in comparison with diazepam. 
Drugs: All drugs used in the extinction experiments were administered 
intra-peritoneally in a volume of 1 ml/kg, 20 minutes before the behavioural 
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experiments started. (±)-Baclofen was dissolved in saline, oxazepam was 
injected as a sonicated suspension in distilled water with a drop of Tween 80 
added. Haloperidol was dissolved in acidified saline (pH 5), other drugs were 
dissolved in a salinejpropyleneglycol 1:1 mixture. In Vogel's conflict test, 
drugs were administered subcutaneously 45 min before the behavioural 
experiment. Baclofen was dissolved in a saline/polypropyleneglycol 9:1 
mixture, while diazepam was administered as a suspension in a mulgofen 5 % 
-saline mixture. The control rats were injected with the salinejpoly-
propyleneglycol vehicle. 
Binding studies. Baclofen pretreatment: The effect of pretreatment of rats 
with baclofen on [3H]-diazepam binding, using a brain membrane preparation, 
was assessed by comparing baclofen with saline injected rats. Doses of 1.5 or 
3 mg/kg of baclofen in a volume of 1 ml/kg were administered intraperitoneally 
30 min before decapitation. 
Preparation of rat brain membranes: Male Wistar rats (200-250 g) were 
decapitated and brains were dissected immediately. Cortex and cerebellum were 
isolated and stored at -70 o C. Homogenization was carried out 1 to 4 days 
later. The cortex of each rat was thawed and homogenized in 10 volumes (w/v) 
of ice-cold 0.32 M sucrose, using a glass-teflon homogenizer (clearance 0.15 
mm, 5 strokes). The suspension was centrifuged for 10 min at 1000 x g. The 
resulting supernatant was divided over 2 centrifuge tubes and was centrifuged 
again for 20 min at 40.000 x g. Of the resulting two membrane pellets, one was 
immediately stored at -70°C and will be referred to as the unwashed cortical 
membrane pellet. The other pellet was resuspended and washed 4 times with 10 
volumes (v/v) of 50 mM Tris-HCl buffer (pH:7.4) before storage at -70°C and 
will be referred to as the washed cortical membrane pellet. The homogenization 
procedure for the cerebellar tissue is actually the same as described for the 
cortical tissue, with the exception that the supernatant was not divided into 
two portions, so that one pellet per cerebellum was obtained after the first 
centrifugation. 
Binding assay: Membrane pellets were thawed and resuspended in a 50 mM 
Tris-HCl buffer (pH:7.4). Binding studies were performed using 5 
concentrations of [3H]-diazepam (specific activity: 90 Ci/mmole, Amersham) 
ranging from 2. 5 to 20 nM. Incubation was performed at 4 o C for 30 min in a 
total volume of 1 ml. Specific [3H]-diazepam binding was determined as the 
difference in membrane bound radioactivity measured in the absence and 
presence of 20 ).1M unlabelled diazepam. Incubation was terminated by rapid 
filtration through Whatman GF/C glass fiber filters. Filters were washed 4 
times with 3 ml of the Tris-HCl buffer and subsequently transferred to 
scintillation vials containing 7 ml of scintillator 299tm (Packard). Vials 
were kept overnight at room temperature. The next day radioactivity was 
measured in a TRI-CARB Scintillation Spectrometer with an efficiency of 32 %. 
Kd and Bmax were calculated from Scatchard plots (30) with the aid of the 
computerized program "LIGAND" (31). Protein concentrations of the membrane 
suspensions per incubation tube were 250-350 pg/ml for cerebellar membranes 
and 500-800 pgjml for cortical membranes and were determined according to 
Bradford (32). 
Statistical analysis. Data were analysed using Student's t-test, parametric or 
non-parametric one way analysis of variance (ANOVA) followed by the 
Student-Newman-Keuls'-test (SNK) or Mann-Whitney U test and Wilcoxon's signed 
rank test. 
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Results 
Behavioural studies: 
Intraperitoneal injection of baclofen or oxazepam resulted in a dose dependent 
increase of extinction of conflict behaviour (Fig. lA). From the log 
dose-response curve, it appears that baclofen is about twice as active as 
oxazepam in enhancing the rate of extinction. Baclofen and diazepam both have 
an anti-conflict effect in Vogel's conflict test (Table I). Baclofen, oxazepam 
and diazepam did not affect responding during unpunished periods in both 
tests, with the exception of 2.5 mgjkg baclofen, where a decrease of 
responding occurred in the extinction experiments (Fig. lB). Higher doses of 
baclofen (data not shown) led to muscle relaxation and sedation in both tests 
which interfered with responding. 
FIG. 1 
EFFECTS OF BACLOFEN {•) AND OXAZEPAM (O) IN THE FRl SCHEDULE. 
DATA ARE MEAN ±S.E.M. (N = 12). 
-No: p<O.OS vs vehicle {c) (ANOVA followed by SNKJ 
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A: Effects of baclofen (e) and oxazepam (o) in the FR 1 schedule. B: Effects 
of baclofen (•) and oxazepam (o) in the 5% (unpunished) schedule. Data are 
means± s.e.m. (N = 12). *: P < 0.05 vs vehicle (c) (ANOVA followed by SNK). 
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Table I 
Effects of Baclofen and Diazepam in Vogel's Conflict Test. 
Drug Dose (mg/kg) Number of licks per rat per 15 min 
n punished n unpunished 
Vehicle (20) 76 ± 12 (20) 1100 ± 65 
Diazepam 0.46 (10) 215 ± 108'" (10) 1309 ± 78 
Diazepam 1.00 (10) 485 ± 134* (9) 1139 ± 109 
Diazepam 4.60 (10) 829 ± 188* (10) 1319 ± 70 
Baclofen 0.46 (10) 158 ± 33'" (10) 1008 ± 80 
Baclofen 1.00 (10) 217 ± 61* (9) 1281 ± 113 
* p < 0.05 vs vehicle (Kruskal-Wallis ANOVA followed by Mann-Whitney U : 
test). 
TABLE II 
Extinction of Conflict Behaviour. 
Dose (mgLkg1 5 % schedule FR 1 schedule n 
Neuroleptics. 
Haloperidol 0.0 1043 ± 146 2.7 ± 0.5 (6) 
0.1 1158 ± 121 2.5 ± 0.4 (6) 
0.3 859 ± 172 8.7 ± 1. 7'"' (6) 
0.5 1198 ± 148 21.8 ± 3.9* (6) 
1.0 55 ± 20 0.6 ± 0 .4'"' (6) 
Chlorpromazine 0.0 963 ± 57 1.3 ± 0.3 (4) 
3.0 970 ± 56 2.3 ± 0.6 (4) 
Thioridazine 0.0 909 ± 134 0.8 ± 0.5 (4) 
5.0 520 ± 131 0.8 ± 0.3 (4) 
Antidepressants. 
Imipramine 0.0 1202 ± 141 1.3 ± 0.5 (4) 
10.0 628 ± 40 2.3 ± 0.9 (4) 
Amitryptiline 0.0 1290 ± 114 2.8 ± 1.0 (8) 
1.0 890 ± 101 4.1 ± 1.2 (8) 
Protryptiline 0.0 1290 ± 114 2.8 ± 1.0 (8) 
0.05 1217 ± 122 3.4 ± 0.7 (8) 
0.1 830 ± 104 13.8 ± 5.4 (8) 
0.5 1043 ± 95 5.4 ± 1.9 (8) 
1.0 657 ± 98 13.5 ± 3.5* (8) 
Mianserine 0.0 1396 ± 191 1.5 ± 0.3 (4) 
1.0 552 ± 140 0.7 ± 0.3 (3) 
* p < 0.05 vs vehicle. (Wilcoxon's signed rank test). 
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In order to test the specificity of the effect of baclofen on extinction of 
conflict behaviour, effects of several other psycho-active drugs were tested. 
Each drug was tested in 3 to 4 doses of which the maximal dose is shown in 
Table II. The results indicated that none of the neuroleptics or 
anti-depressants, with the exception of haloperidol and protryptiline had a 
significant effect on extinction. The doses of haloperidol used, had no effect 
on punished behaviour in the presence of foot shock. Protryptiline was not 
tested in the latter situation. 
Binding studies: 
Binding was determined in unwashed and washed membranes to investigate a 
possible effect of a baclofen induced change in the level of GABA or another 
factor in vitro. In one series of experiments (±)-bicuculline was added to the 
incubation mixture (concentration per incubation tube: 100 j.JM) in order to 
prevent GABA-A mediated effects on the benzodiazepine receptor (1,2). As shown 
in Table III, washing of the cortical membranes significantly increased Kd as 
well as Bmax of the benzodiazepine receptors. The presence of bicuculline did 
not affect Bmax significantly, while Kd increased in washed as well as 
unwashed membranes to a value of about 15 nM. Pretreatment of the rats with 
baclofen was without effect on Bmax and Kd. 
In analogy with the cortical tissue, the Kd and the Bmax of cerebellar 
membranes for diazepam were also significantly increased after washing (Table 
IV). However, in these preparations bicuculline did not further increase the 
Kd of washed membranes. Another difference with cortical tissue, was that 
bicuculline addition decreased the Bmax significantly. A third difference was 
the small but significant increase of Bmax in washed, bicuculline containing 
membrane preparations, obtained from brains of baclofen pretreated rats. 
Incubation of washed and unwashed cortical and cerebellar membranes in the 
presence of baclofen (25-400 pM) did not affect [3H]-diazepam binding (data 
not shown). 
TABLE III 
[ 3H]-Diazepam Binding to Cortical Membranes. 
+ BICUCULLINE. 
bacl. 
mg/kg Kd: Bmax: Kd: Bmax: 
UNWASHED 
0 6.1 ± 0.2 0.92 ± 0.03 (8) 15.9 ± 1.1** 0.89 
1.5 6.6 ± 0.3 0.94 ± 0.03 (8) 15.5 ± 1. 7>b'< 0.94 
3 5.4 ± 0.5 0.86 ± 0.04 (4) 14.3 ± 0. 4'''"* 0.91 
WASHED 
0 9.3 ± o. 5'"' 1.41 ± 0.06* (6) 14.3 ± o. 5*"' 1.25 
1.5 11.3 ± l. 9'"' 1.46 ± 0.04* (4) 15.4 ± 1.4 l. 34 
3 7.9 ± 0.7* l. 31 ± 0.09"' (4) 13.3 ± o. 5"'* l. 28 
Kd: nM. Bmax: pmoljmg protein. Bicuculline cone.: 100 j.JM. 
Number of animals are given in parentheses. 
± 
± 
± 
± 
± 
± 
0.02 
0.05 
0.03 
o. 05'"' 
0. 03'"' 
0.03* 
>'< : P < 0.05 vs unwashed (Student's t-test). 
*'\: : P < 0.05 vs without bicucul1ine addition (Student's t-test). 
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(4) 
(4) 
(4) 
(4) 
(4) 
(4) 
TABLE IV 
[ 3H]-Diazepam Binding to Cerebellar Membranes. 
+ BICUCULLINE. 
bacl. 
mgjkg Kd: Bmax: Kd: Bmax: 
UNWASHED 
0 4.8 ± 0.3 0.70 ± 0.03 (8) 15.0 ± 1. 8*i< 0.61 ± 0.01'''"* (4) 
1.5 5.9 ± 0.2 0.70 ± 0.02 (4) 14.4 ± 1.4*'~ 0.64 ± 0.06 (4) 
3 5.4 ± 0.4 0.75 ± 0.03 (4) 13.7 ± L 8*'~ 0.61 ± 0. 03'~* (4) 
WASHED 
0 15.2 ± 1. 6* 0.99 ± 0. 06''< (7) 12.1 ± 1.0 0.81 ± 0.01*.,.< (4) 
1.5 13.5 ± 1.7* 1.04 ± 0. 02'~ (4) 15.0 ± 1.2 0.92 ± 0. 04''<*+ (4) 
3 14.2 ± 1.4* 0.99 ± 0. 031< (4) 15.4 ± 0.9 0.93 ± 0.04+ (4) 
Kd: nM. Bmax: pmoljmg protein. Bicuculline cone.: 100 pM. 
Number of animals are given in parentheses. 
+ p < 0.05 vs saline (ANOVA followed by SNK). 
* p < 0.05 vs unwashed (Student's t-test). 
** p < 0.05 without bicuculline addition (Student's t-test). vs 
Discussion 
It has been shown by Quintero et al. (25,33,34) and Buckland et a1. (35) that 
baclofen affects behaviour of rats in several tests in a complicated manner, 
suggesting anxiolytic but also anxiogenic activity. 
The present results show that administration of baclofen to rats enhanced 
extinction of conflict behaviour in a dose dependent manner. Baclofen did not 
affect punished behaviour when foot shock was activated in the Geller-Seifter 
test (unpublished results), which is in agreement with the results obtained 
by Quintero et al. (25). However, the dose range of baclofen used had to be 
limited because doses above 2.5 mg/kg caused sedation and paresis of the hind 
legs and thus interfered with responding. Low doses of oxazepam (without 
effect on punished behaviour in the Ge1ler-Seifter test), were used in the 
extinction experiments. In this dose range oxazepam enhanced extinction of 
conflict behaviour in a dose dependent manner. Baclofen seemed to be about 
twice as active as oxazepam in enhancing extinction. It is however difficult 
to state this with certainty since baclofen was administered as a solution 
while oxazepam was administered as a suspension. Observation of the animals 
during the tests on extinction of conflict behaviour revealed that after 
presentation of the discriminative stimulus, the rats displayed "conflict 
behaviour" before their first lever pressing, i.e. they approached to- and 
backed away from- the lever several times without pushing it. Saline injected 
rats only sporadically pushed the lever during the test session, while 
baclofen and oxazepam treated rats showed extinction of conflict behaviour 
after a short response latency. Once the first responses were made, the rate 
of lever pressings accelerated. 
In order to further evaluate the effect of baclofen on punished behaviour, 
Vogel's conflict test was·used. In contrast with the Geller-Seifter conflict 
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test, baclofen displayed anti-conflict activity. The results obtained with 
control (unshocked) rats in the latter test indicate that baclofen affected 
only conflict behaviour, which makes it unlikely that an increased locomotor 
activity or a dipsogenic effect is playing a role in the observed effects. In 
order to show the specificity of a drug-induced increase of extinction of 
conflict behaviour, other psycho-active drugs were tested. Of the neuroleptics 
only haloperidol had an effect comparable to baclofen. Of the anti-
depressants tested, only protryptiline increased extinction. Haloperidol 
(0.1-1.0 mg/kg) did not affect responding when foot shock was activated (data 
not shown) as has also been shown previously by Cook and Davidson (27). 
Protryptiline was not tested in the latter situation. Therefore the effect of 
baclofen on extinction of conflict behaviour was rather specific since 
anti-depressants and neuroleptics were ineffective, while a similarity in 
effect exists between baclofen and oxazepam. A second similarity in effect 
between baclofen and a benzodiazepine is observed in Vogel's conflict test. If 
extinction of conflict behaviour and an increase in punished licking form 
aspects of the anxiolytic activity of the benzodiazepines, one may suggest 
that also GABA-B receptor activation will have anxiolytic activity. 
The behavioural results obtained may be explained by the following actions: 
(a) baclofen and the benzodiazepines both act via the GABA-Ajbenzodiazepine 
receptor/chloride channel complex, (b) baclofen and the benzodiazepines both 
act via the GABA-B system, or (c) the mode of action is different for both 
drugs. Considering the first possibility, it has been shown that in contrast 
with activation of the GABA-A receptor, GABA-B receptor activation in vitro 
does not increase the affinity of benzodiazepine receptors. (11, 12). Also 
under our experimental conditions baclofen (25-400 pM) did not affect Kd or 
Bmax of [3H]-diazepam binding (data not shown). Thus in vitro experiments do 
not support a direct effect of baclofen on the GABA-A/benzodiazepine 
receptor/chloride channel complex. Although the evidence is equivocal, there 
are indications that baclofen may cause GABA release (13, 14) and this may 
explain the common effect of the benzodiazepines and baclofen on conflict 
behaviour. One therefore may expect that in vivo administration of 
behaviourally active doses of baclofen will increase the affinity of 
benzodiazepine receptors in vitro by increasing GABA release in vivo. However, 
no effect on Kd and Bmax of [3H]-diazepam binding in unwashed cortical and 
cerebellar membranes, obtained from baclofen pretreated rats, could be shown 
and therefore no support for an enhanced release of GABA in vivo by baclofen 
was obtained. 
The increase in Kd in washed preparations and in the presence of the GABA-A 
antagonist bicuculline is probably due to the partial removal of GABA from the 
membrane preparations (36). This interpretation is supported by bicuculline's 
effect on the affinity of diazepam for the benzodiazepine receptor in crude 
membrane preparations (37). The significant decrease in affinity in 4x washed 
cortical membranes as compared to unwashed membranes is similar to that found 
by Chiu and Rosenberg (37). This effect has been well documented (2). 
While pretreatment of rats with baclofen did not affect [3H]-diazepam binding 
in a cortical membrane preparation, in cerebellar membranes a small but 
significant Bmax increase was found using washed membrane preparations 
incubated in the presence of bicuculline. These results suggest that baclofen 
is able to increase the Bmax of benzodiazepine receptors probably in a limited 
number of sites in cerebellar tissue since the increase was small (13 %) . 
Furthermore, only after inactivation of the GABA-A receptor a GABA-B 
interaction on benzodiazepine receptor sites could be demonstrated and, 
secondly, the increase in Bmax could only be shown after washing and not in an 
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unwashed preparation in the presence of bicuculline. The mechanism behind this 
effect of baclofen remains to be established. 
The increase in Bmax observed in cortical and cerebellar membranes after 
washing with Tris buffer has been reported previously (37,38). The removal of 
a diazepam binding inhibitor, possibly acting as an endogenous ligand for the 
benzodiazepine receptor has been suggested as one of the mechanisms 
responsible for this effect (39-45). Therefore the effect of baclofen 
treatment on Bmax in washed cerebellar membrane preparations and the absence 
of effect in unwashed preparations indicates an opposite effect of baclofen 
treatment and the putative endogenous ligand; removing the binding inhibitor 
will unmask the effect of baclofen. But it is, however, unlikely that the 
behavioural effects of baclofen can be ascribed to the mechanisms discussed 
above. 
The second possibility, a common effect of baclofen and benzodiazepines via 
the GABA-B system, is also not likely as the benzodiazepines enhance the 
effects of the neurotransmitter GABA at the level of the GABA-Ajbenzodiazepine 
receptor complex, and not via altered GABA release, uptake or catabolism. 
Thus, benzodiazepines do not affect the level of GABA-B receptor activation in 
an indirect way (review: 46). In addition, it has been reported that 
benzodiazepines do not affect binding of GABA to the GABA-B receptor (11). 
Final proof for the non-involvement of the GABA-Ajbenzodiazepine receptor 
complex has to come from behavioural experiments investigating whether 
GABA-Ajbenzodiazepine receptor antagonists affect the observed baclofen 
effects. Finally, it is possible that benzodiazepines and baclofen both affect 
the function of another neurotransmitter involved in punished behaviour. Among 
the possible candidates are the serotonergic and dopaminergic systems, which 
are both related to the GABA-Ajbenzodiazepine receptor complex and the GABA-B 
receptor and are involved in behavioural suppression induced by aversive 
stimuli (47-50). 
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CHAPTER III 
THE ANTI-CONFLICT EFFECT OF CYPROHEPTADINE IS NOT MEDIATED BY 
ITS 5-HYDROXYTRYPTAKINE ANTAGONISTIC PROPERTY. 
C.E.J.Ketelaars and J.Bruinvels. 
published in Life Sciences 44:1743-1749, 1989 
Summary 
Cyproheptadine, a 5HT2 receptor antagonist with prominent anti-muscarinic and 
anti-histaminic properties, was shown to have an anti-conflict effect in rats 
using a modified Geller-Seifter test and also enhanced extinction of conflict 
behaviour. The selective 5HT2 receptor antagonist ritanserin, however, had 
neither an anti-conflict effect nor an effect on extinction of conflict 
behaviour. The muscarinic receptor antagonist scopolamine, on the other hand, 
was active in both paradigms. The effect of cyproheptadine on extinction of 
conflict behaviour was decreased by co-administration of physostigmine, an 
acetylcholinesterase inhibitor, but not affected by the concomitant 
administration of the muscarine receptor agonist oxotremorine. The results 
suggest that the anti-conflict effect of cyproheptadine has to be ascribed to 
its anti-muscarinic activity and is not due to its 5HT2 antagonism. 
Introduction 
The action of benzodiazepines in rat conflict models has been ascribed to a 
facilitation of the GABA-ergic system (1). In addition, it has been suggested 
that this anti-conflict effect occurs via modulation of the serotonergic (5HT) 
system (2). In agreement with this, it has been shown that activation of the 
GABA-Ajbenzodiazepine receptor complex exerts an inhibitory effect on 5HT 
neurones (3). Investigations using drugs that alter 5HT activity, have indeed 
been shown to change behaviour in animal anxiety models (4,5). Cyproheptadine 
has been shown to be active in animal studies on conflict behaviour 
(6,7,8,9,10,11). This effect has been ascribed to its 5HT antagonistic 
property (7,8,9,10,11). 
As proposed by Bradley et al (12), central 5HT receptors can be subdivided 
into 5HT1A, B and c, 5HT2 and 5HT3 receptors. Cyproheptadine has 5HT2, 
muscarine and histamine blocking properties (13, 14,15). The present 
availability of the highly selective 5HT2 antagonist ritanserin (16,17) makes 
it now possible to compare the behavioural effects of cyproheptadine with 
those of ritanserin in order to relate the effects of cyproheptadine to its 
5HT2 blocking action or to one of its other properties. 
Two aspects of conflict behaviour were studied; anti-conflict effect, (i.e. 
increase of punished (foot shock) responding) and extinction of conflict 
behaviour, (i.e. responding after disconnection of the foot shock generator 
(18)). Extinction of conflict behaviour was chosen as an additional model for 
detecting anxiolytic activity of drugs. This model is based on the idea that 
anxiety neurosis in patients often occurs without the presence of a conflict 
situation. It was therefore assumed that these patients may suffer from an 
impaired extinction of a previously experienced anxiety-provoking event. As 
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shown previously, extinction of rat conflict behaviour has been shown to be a 
more sensitive behavioural test for detecting drugs with anxiolytic properties 
than conflict behaviour itself (18). 
Methods 
In order to study conflict behaviour the Geller-Seifter test (19) was used as 
has been described previously (18,20). In brief: After being deprived of water 
for 16 hours, male Wistar rats (starting weight: 70 - 90 g; after training was 
completed: 250 - 350 g) were placed in an experimental chamber measuring 20 x 
20 x 20 em, containing a response lever, milk delivery apparatus, an 
electrifiable grid floor and a stimulus light. The rats were trained to press 
a lever in order to obtain milk and were subsequently trained once a day for a 
duration of 42 minutes. Within these training (and test) periods, two 
schedules were used in alternation. During 5 minutes a 5 % random interval 
(RI) schedule was offered. This schedule was alternated with 2 minutes of a 
fixed ratio 1 (FR 1) schedule. A steady light signal during the FR 1 schedule 
served as the stimulus by which the animals were able to discriminate between 
both schedules. This combination of RI and FR 1 schedules was presented 6 
times to each rat per session. After stabilization of performance, 
response-contingent foot shock was given during the FR 1 periods. Shock levels 
(100-160 V, 2 3. 3 rnA) were individually adjusted until cumulative lever 
pressings during the FR 1 periods were below 5 per 12 minutes, which 
represents about 5 % of the number of lever pressings before foot shock was 
applied. Drug effects on conflict behaviour were measured each time after at 
least 2 days of training in order to achieve a stable "base line" level of 
conflict behaviour. Extinction of conflict behaviour was measured in the same 
way using the same procedure except that foot shock was turned off. Between 
test days training continued in the presence of foot shock, and shock levels 
were adjusted when the animals took more than 5 shocks per 12 minutes. After 
at least 20 training sessions, spontaneous extinction was virtually 
non-existent in control rats during the trial period; i.e. these animals 
responded with an average of 0 to 5 pressings per 12 minutes. Four groups of 
12 rats were used. Two groups were used in the conflict test and two in the 
extinction experiments. Vehicle and different doses of each drug were 
administered to each rat of a group using a latin square design. The effects 
of drugs were tested once a week to allow for a sufficiently long wash out 
period. 
Drugs: All drugs used were administered intraperitoneally in a volume of 1 
ml/kg. Cyproheptadine-HCl (MSD), scopolamine-HEr (Sigma), oxotremorine-
sesquifumarate (Aldrich) and physostigmine-salicylate (Sandoz) were dissolved 
in saline and injected 10 minutes before the behavioural experiments started. 
Doses are expressed as the salt in mg/kg. Oxazepam and ritanserin were 
administered 20 minutes before the experiment as a sonicated suspension in 
distilled water with a drop of Tween 80 added. Doses were expressed as the 
base in mgjkg. Oxazepam was kindly donated by Wyeth, ritanserin was kindly 
donated by Janssen Pharmaceutica. 
Statistical analysis. Data were analysed using Student's t-test or by 
parametric or non-parametric one way analysis of variance (ANOVA) followed by 
Student-Newman-Keuls'-test or the Mann-Whitney U test respectively. 
Results 
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Administration of 7 or 10 mg/kg cyproheptadine to the rats resulted in an 
increase in responding during the FR 1 schedules in both conflict and 
extinction tests (Table I). No effect occurred on the level of responding 
during the random interval schedule. 
When ritanserin (20 mg/kg i.p.) was used instead of cyproheptadine, no effect 
could be found in both behavioural tests (Table II). Lower doses of ritanserin 
(2.5 and 10 mg/kg i.p.) were also ineffective as well as an oral dose of 10 
mg/kg (data not shown). Oxazepam (15 mg/kg) was active under both conditions. 
TABLE I 
Effects of Cyproheptadine on Conflict Behaviour. 
Conflict behaviour Extinction of conflict behaviour 
Dose RI FRl n RI FRl n 
(mg/kg) schedule schedule schedule schedule 
0.0 991 ± 299 0.6 ± 0.2 (7) 994 ± 175 12.4 ± 7.8 (7) 
Cyproh 7.0 1384 ± 334 2.4 ± 0.7* (7) 1057 ± 221 49.4 ± 13. 3'~ (7) 
0.0 1225 ± 145 1.3 ± 0.2 (12) 1381 ± 180 27.5 ± 10.6 (12) 
Cyproh 10.0 1164 ± 199 5.2 ± 0.7* (12) 964 ± 231 70.3 ± 9. 8'" (12) 
*: P < 0.05 vs vehicle (Student's t test). Cumulative level of responding per 
session during random interval (RI) and fixed ratio 1 (FR 1) schedule per 30 
and 12 min respectively. Data are mean ± s.e.m. 
TABLE II 
Effects of Oxazepam and Ritanserin on Conflict Behaviour. 
Conflict behaviour Extinction of conflict behaviour 
Dose RI FR 1 n RI FRl n 
(mg/kg) schedule schedule schedule schedule 
0.0 1893 ± 149 1.1 ± 0.4 (8) 1871 ± 215 16.5 ± 10.8 (8) 
Oxaz 15.0 1792 ± 195 9.1 ± 5.4* (8) 1660 ± 157 165.0 ± 40. 7'< (8) 
Ritans 20.0 1522 ± 126 2.0 ± 0.4 (8) 1616 ± 154 2.5 ± 0.8 (8) 
* : P < 0.05 vs vehicle (Kruskal-Wallis ANOVA followed by Mann-Whitney U 
test). Cumulative level of responding per session during RI and FR l schedule 
per 30 and 12 min respectively. Data are mean ± s.e.m. 
Scopolamine, a muscarlnlc receptor antagonist, was administered to rats and 
its effect on conflict behaviour recorded. As shown in table III, scopolamine 
had an anti-conflict effect and enhanced extinction of conflict behaviour. The 
highest dose of scopolamine (0.2 mg/kg) also caused a significant decrease of 
responding during the random interval schedule. Gross behavioural disturbances 
were not observed. 
In order to see whether an increased availability of acetylcholine could 
antagonize the effect of cyproheptadine, the acetylcholinesterase inhibitor 
physostigmine was administered in a dose of 0.25 mg/kg immediately followed by 
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cyproheptadine. The drugs were administered 10 minutes before the start of the 
experiment. The effect of cyproheptadine on extinction of conflict behaviour 
was counteracted when the rats were treated simultaneously with physostigmine, 
while the number of responses during the random interval schedule was not 
affected (Table IV). Administration of physostigmine alone resulted in a 
significant decrease in the number of responses during FR 1 and RI schedules. 
Under this condition pronounced chewing and licking, mild tremor and 
occasional stretching was noted. 
TABLE III 
Effects of Scopolamine on Conflict Behaviour. 
Conflict behaviour Extinction of conflict behaviour 
Dose RI FRl n RI FR 1 n 
(mg/kg) schedule schedule schedule schedule 
0.0 1095 ± 252 1.2 ± 0.4 (9) 1250 ± 267 1.0 ± 0.3 (5) 
Scopol 0.05 1029 ± 332 2.9 ± 0.7 (7) 1444 ± 473 0.8 ± 0.6 (5) 
0.1 450 ± 110 2.9 ± 0.6* (9) 1262 ± 465 8.4 ± 6.4 (5) 
0.2 285 ± 164'" 9.3 ± 6.1* (8) 284 ± 123 43.8 ± 12. 7'" (5) 
* : P < 0.05 vs vehicle (Kruskal-Wallis ANOVA followed by Mann-Whitney U 
test). Cumulative level of responding per session during RI and FR 1 schedule 
per 30 and 12 min respectively. Data are mean± s.e.m. 
TABLE IV 
Effects of combined administration of Cyproheptadine and 
Physostigmine on Extinction of Conflict Behaviour. 
Extinction of conflict behaviour. 
Dose RI 
(mgjkg) schedule 
0.0 1152 ± 328 
Cyproheptadine 10.0 1190 ± 255 
Cyprohjphysos 10.0/0.25 872 ± 254 
0.0 1216 ± 165 
Physostigmine 0.25 14 ± 10$ 
FR 1 n 
schedule 
1.3 ± 0.7 (8) 
42.4 ± 12.2* (8) 
12.0 ± 6.2 (7) 
1.6 ± 0.4 (5) 
o.o ± o.o$ (5) 
* : P < 0.05 vs vehicle and vs cyproheptadine/physostigmine (Kruskal-Wallis 
ANOVA followed by Mann-Whitney U test). 
$ P < 0.05 vs vehicle (Student's t test). 
Cumulative level of responding per session during RI and FR 1 schedule per 30 
and 12 min respectively. Data are mean± s.e.m. 
Administration of 0.08 mg/kg oxotremorine, a muscarinic (Mz) agonist, 
increased responding during the FR 1 schedule in the conflict as well as in 
the extinction experiments while a significant decrease of responses during 
the random interval schedules occurred (Table V). After administration of 0.08 
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mg/kg oxotremorine, the following behavioural signs were observed: flat body 
posture, abducted hindlimbs, piloerection, chewing, hyperlocomotion and 
tremors. Oxotremorine was not able to counteract the effect of cyproheptadine 
on extinction of conflict behaviour. However, the behavioural syndrom observed 
after oxotremorine (0.08 mg/kg) was not present when cyproheptadine was 
administered immediately after administration of oxotremorine. 
TABLE V 
Effects of Oxotremorine on Conflict Behaviour. 
Conflict behaviour Extinction of conflict behaviour 
Dose RI FR 1 n RI FRl n 
(mg/kg) schedule schedule schedule schedule 
0.0 1100 ± 274 1.3 ± 0.4 (10) 975 ± 151 2.9 ± 1.5 (9) 
Oxotr 0.04 613 ± 153 2.0 ± 0.5 (10) 476 ± 214 30.2 ± 12.1 (9) 
0.08 24 ± s* 3.7 ± 1.0* (9) 80 ± 23* 38.8 ± 12.5* (8) 
* : P < 0.05 vs vehicle parametric one way ANOVA followed by Student-Newman-
Keuls' test. Cumulative level of responding per session during RI and FR 1 
schedule per 30 and 12 min respectively. Data are mean± s.e.m. 
TABLE VI 
Effects of combined administration of Cyproheptadine and 
Oxotremorine on Extinction of Conflict Behaviour 
Extinction of conflict behaviour 
Dose RI FR 1 n 
(mg/kg) schedule schedule 
0.0 1100 ± 280 0.7 ± 0.3 (6) 
Cyproheptadine 10.0 555 ± 138 39.9 ± 15 .1'" (8) 
Cyprohjoxotr 10.0/0.04 854 ± 342 58.5 ± 19.0* (6) 
Cyprohjoxotr 10.0/0.08 848 ± 365 41.2 ± 12.0* (5) 
Cyprohjoxotr 10.0/0.16 610 ± 241 70.8 ± 18. 2'" (4) 
* P < 0.05 vs vehicle (Kruskal-Wallis ANOVA followed by Mann-Whitney U 
test). Cumulative level of responding per session during RI and FR 1 schedule 
per 30 and 12 min respectively. Data are mean ± s.e.m. 
Discussion 
The effects of cyproheptadine observed in several animal models for anxiety 
have been ascribed to its SHT receptor blocking action (7,8,9,10,11). Since at 
present more ~elective SHT antagonists are available and the receptor binding 
profile of cyproheptadine has meanwhile been established, it is now possible 
to determine in a more definitive way whether the anti-conflict effect of 
cyproheptadine is caused by its 5HT2 antagonistic property. Behavioural 
experiments and receptor binding studies indicate that cypro-heptadine, 
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besides its SHT2 antagonism, also blocks histamine and muscar~n~c receptors 
(13,14,15). The present results indicate that cyproheptadine, like 
benzodiazepines (18), released punished behaviour and increased extinction of 
conflict behaviour. However, this effect did not seem to be related to its 
SHT2 receptor blocking property since the specific SHT2 antagonist ritan-
serin was without effect. This failure of ritanserin to enhance extinction of 
conflict behaviour is in agreement with other reports showing that ritanserin, 
in doses comparable to those used in the present study, is not active in three 
other conflict paradigms (7,17,21). Binding data indicate that ritanserin is a 
highly selective ligand for 5HT2 receptors (16, 17, 22). It is reported that 
0.63 mg/kg given subcutaneously results in a full occupation of SHT2 receptors 
in the central nervous system, while doses up to 160 mg/kg ( s. c.) do not 
affect binding of ligands to adrenoceptors or dopamine receptors (22). 
Although ritanserin has been reported to possess some affinity to the 
histamine (H1) receptor, the IC50 of ritanserin for this receptor is 35 times 
higher (35 nM) than that for the 5HT2 (1 nM) receptor (22). In the present 
experiments, ritanserin was used in a dose (20 mg/kg) which blocks SHT2 
receptors completely (22), and which is unlikely to affect H1 receptors. The 
results therefore indicate that the 5HT2 blocking property of cyproheptadine 
can not be held responsible for the anti-conflict effects. This conclusion is 
supported by the lack of effect of mianserin, another SHT2 antagonist, on 
extinction of conflict behaviour (18). 
The doses of cyproheptadine used in the present experiments make it very 
unlikely that the weak histamine receptor blocking property of this compound 
is responsible for the anti-conflict effect. This inference is supported by 
Graeff (11) who was not able to demonstrate the release of punished behaviour 
by a number of anti-histaminics. 
The only property left to explain the anti-conflict effects of cyproheptadine 
is therefore its muscarinic receptor blocking property. Administration of 
scopolamine, a selective muscarinic receptor antagonist (23), was shown to 
increase responding during punishment and enhanced the extinction of conflict 
behaviour. These effects indeed point to the possibility that the anti-
cholinergic property of cyproheptadine was responsible for the observed 
behavioural effect. However, in contrast to cyproheptadine, scopolamine 
increased responding during the FR 1 schedule at doses which decreased 
unpunished responding. Nevertheless, supporting evidence for a role of the 
muscarinic receptor blocking property of cyproheptadine was obtained by co-
administration of the cholinesterase inhibitor physostigmine which 
counteracted the enhanced extinction of conflict behaviour evoked by cypro-
heptadine. It is well established that muscarinic receptor subtypes M1 and M2 
exist (24). Muscarinic receptor antagonists generally are non-selective or 
have been shown to act preferentially as M1 antagonists (25). Since the 
muscarinic agonist oxotremorine preferentially binds to M2 receptors which in 
part may function as autoreceptors on cholinergic nerve fibers (25), it is 
conceivable that oxotremorine will impair acetylcholine release. This 
mechanism may explain the results of oxotremorine on the release of punished 
behaviour and on the increased extinction of conflict behaviour. The M1 
blocking activity of cyproheptadine and the decreased release of acetylcholine 
by the M2 agonist oxotremorine are both responsible for an impaired 
cholinergic transmission which may thus explain the observed anti-conflict 
effects of both drugs. However, in contrast to cyproheptadine, administration 
of oxotremorine induced a number of cholinergic effects (tremor, chewing and 
piloerection) which were not seen after the admini-stration of cyproheptadine. 
The finding that· these effects of oxotremorine did not occur after the 
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concomitant administration of cyproheptadine suggest that these cholinergic 
effects of oxotremorine may be caused by its M1 agonistic action. However, 
further experiments are needed to support this latter explanation. 
In conclusion, the present results indicate that the anti-conflict effects of 
cyproheptadine can not be ascribed to its well known 5HT2 antagonistic 
property but seem to be the result of its M1 blocking activity. 
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CHAPTER IV 
IMPAIRED 5-HT FUNCTION ENHANCES EXTINCTION OF CONFLICT BEHAVIOUR 
C.E.J. Ketelaars and J. Bruinvels 
submitted for publication 
Summary 
In order to investigate whether a decreased function of the serotonergic (5-
HT) system affects extinction of conflict behaviour in a way similar to 
baclofen, the effect of PCPA, 8-0H-DPAT, ICS 205-930 and propranolol on 
extinction was studied. PCPA, 8-0H-DPAT and propranolol enhanced extinction 
while ICS 205-930 was not effective. The selective f>-adrenoceptor blockers 
butoxamine and metoprolol did not enhance extinction. The doses of propranolol 
which enhanced the extinction of conflict behaviour were in the same dose 
range as those used to inhibit the 5-HT syndrome induced by 8-0H-DPAT. In PCPA 
pretreated rats, baclofen and 8-0H-DPAT were not any more able to enhance 
extinction. The present results suggest that an impaired 5-HT system induced 
an enhancement of extinction of conflict behaviour and may be involved in the 
previously described effect of baclofen on extinction. 
Introduction 
The anti-conflict effect of the benzodiazepines has been ascribed to a 
facilitation of the GABA-ergic system (Haefely 1978; Sepinwall & Cook 1984; 
Quintero et al. 1985; Zakusov et al. 1977; Scheel-Kruger and Petersen 1982; 
Velluci and Webster 1984) . Besides, it has been proposed that the benzo-
diazepines might affect conflict behaviour via modulation of the 5-HT system 
(Wise et al. 1972; Stein et al. 1973). Both these theories may be valid since 
activation of the GABAA-benzodiazepine receptor chloride channel complex has 
been shown to exert an inhibitory effect on 5-HT neurons (Wise et al. 1972; 
Gallager 1978). 
Baclofen has been shown to decrease the release of 5-HT from rat cortical 
tissue via activation of presynaptically located GABAB receptors (Schlicker et 
al. 1984; Gray and Green 1987). Furthermore, activation of the GABAB receptor 
and of the 5-HTlA (auto)receptor have both been shown to inhibit the opening 
of a shared potassium-channel in the hippocampus and the raphe nuclei (Innis 
and Aghajanian 1987; Andrade et al. 1986). 
However, in contrast to the benzodiazepines, baclofen does not cause an anti-
conflict effect in the Geller- Seifter test, but both increase extinction of 
conflict behaviour (Ketelaars et al. 1988). 
It is therefore conceivable that baclofen and the benzodiazepines both exert 
their effect on the extinction of conflict behaviour by a modulation of the 5-
HT system. A reduction in 5-HT neurotransmission has been suggested to 
decrease anxiety while stimulation of the 5-HT system may evoke anxiety (see 
review by Chopin and Briley (1987). Several compounds which modulate the 
activity of the 5-HT system have indeed been shown to have an effect in some 
animal models for anxiety (Chopin and Briley 1987). 
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The aim of the present study was to investigate whether modulation of the 5-
HT system affects extinction of conflict behaviour, an experimental situation 
which has been shown to be more sensitive than anti-conflict effect itself, 
and whether a relationship exists between the 5-HT system and baclofen with 
regard to this behaviour. 
Methods 
Conflict behaviour and extinction of conflict behaviour. In order to study 
conflict behaviour the Geller-Seifter test (Geller and Seifter 1960) was used 
as described previously (Ketelaars et al. 1988). In brief: After being 
deprived of water for 16 hours, male Wistar rats (starting weight: 70 - 90 g; 
after training was completed: 250 - 350 g) were placed in an experimental 
chamber measuring 20 x 20 x 20 em, containing a response lever, milk delivery 
apparatus, an electrifiable grid floor and a stimulus light. The rats were 
trained to press a lever in order to obtain milk and were subsequently trained 
once a day for a duration of 42 minutes. Within these training (and test) 
periods, two schedules were used in alternation. During 5 minutes a 5 % random 
interval (RI) schedule was offered. This schedule was alternated with 2 
minutes of a fixed ratio 1 (FR 1) schedule. A steady light signal during the 
FR 1 schedule served as the discriminative stimulus. This combination of RI 
and FR 1 schedules was presented 6 times to each rat per session. After 
stabilization of performance, response-contingent foot shock was given during 
the FR 1 periods. Shock levels (100-160 V, 2 3. 3 rnA) were individually 
adjusted until cumulative lever pressings during the FR 1 periods were below 5 
per 12 minutes, which represents about 5 % of the number of lever pressings 
before foot shock was applied. Drug effects on conflict behaviour were 
measured on the third day, always after 2 days of training in order to achieve 
a stable "base line" level of conflict behaviour. 
Drug effects on extinction of conflict behaviour were measured in the same way 
using the same procedure except that foot shock was turned off. During the 2 
days before the test days training continued in the presence of foot shock, 
and shock levels were adjusted when the animals took more than 5 shocks per 12 
minutes. After at least 20 training sessions, spontaneous extinction was 
non-existent in control rats during the trial period; i.e. these animals 
responded with an average of 0 to 5 pressings per 12 minutes. 
Eight groups of 12 rats were used. Four groups were used in the conflict test 
and four in the extinction experiments. Vehicle and different doses of each 
drug were administered to each rat of a group using a latin square design. The 
effects of drugs were tested once a week to allow for a sufficiently long wash 
out period. 
5-HT behaviour. The 5-HT behaviour was measured as described by Deakin and 
Green (1978) and Kennett et al. (1985). Male Wistar rats weighing 250 ± 50 
grams were used. After administration of 1.0 mg/kg 8-0H-DPAT, 5-HT behaviour 
was evaluated after 6, 12, 18, 24 and 30 minutes. The four components of the 
syndrome were scored each time by counting piano playing and head weaving for 
a period of 1 minute per animal. Flat body posture and hind limb abduction 
were scored by assessment of intensity (0-1-2-3 for absent-just present-
present-extreme). Propranolol was injected 25 minutes before administration of 
8-0H-DPAT. The scorer was blind to the treatment. 
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Drugs. All drugs used were administered intraperitoneally in a volume of 1 
ml/kg, except p-chlorophenylalanine (PCPA) which was administered in 2 ml/kg. 
8-0H-DPAT was dissolved in saline and injected immediately before the start of 
the experiment, ICS 205-930, propranolol-HCl, butoxamine-HCl, metoprolol 
tartrate and baclofen were dissolved in saline and injected 20 minutes before 
the experiments started. PCPA was dissolved in saline (acidified with HCl and 
brought to pH 6 with NaOH) and administered 17 hours before the experiments. 
The time between treatment and test procedure was chosen in accordance with 
that reported by Koe and Weissman (1966), who have shown an 80% decrease in 
brain 5-HT level after administration of comparable doses of PCPA. It was not 
possible to test at the time of the maximum effect of PCPA (90 % decrease 
after 72 hours), because the PCPA treatment might then interfere with the 
training-phase of the animals. Control animals were injected with the proper 
vehicle. (±)-Baclofen was kindly donated by Ciba-Geigy, ICS 205-930 was kindly 
donated by Sandoz. Butoxamine-HCl was kindly donated by Wellcome Nederland 
B.V. Other drugs were obtained from commercial sources. 
Statistical analysis. Data were analysed using (Kruskal-Wallis) non-parametric 
one way analysis of variance (ANOVA) followed by the Mann-Whitney U test. 
Results 
Administration of graded doses of 8-0H-DPAT resulted in a dose dependent 
increase in responding during the FR 1 schedule in the extinction experiments 
(Table 1). However, no effect of 8-0H-DPAT could be detected during the FRl 
schedule in the conflict experiments (left column table 1). When the highest 
dose of 8-0H-DPAT was used (0.1 mg/kg), a significant decrease in the number 
of responses was observed during the random interval schedule. Since some 
signs of 5-HT behaviour (hyperactivity, flat body posture) were observed after 
administration of this dose of 8-0H-DPAT, it could not be excluded that these 
signs were interfering with the level of responding during the RI schedule. 
Administration of the tryptophan hydroxylase inhibitor PCPA also caused a dose 
related increase in extinction of conflict behaviour during the FRl schedule 
without affecting conflict behaviour itself (Table 2). 
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Table l 
Effect of 8-0H-DPAT on conflict behaviour and extinction of conflict behaviour 
Conflict behaviour Extinction of conflict behaviour 
8-0H-DPAT 
Dose RI FRl RI FRl 
(mg/kg) schedule schedule n schedule schedule n 
0.0 988 ± 241 1.0 ± 0.3 (5) 1129 ± 170 2.0 ± 0.9 (9) 
0.0125 1313 ± 294 1.0 ± 0.3 (5) 1162 ± 135 2.2 ± 1.5 (9) 
0.025 1626 ± 237 1.0 ± 0.6 (5) 1200 ± 185 9.7 ± 3.7 (9) 
0.05 1088 ± 234 1.2 ± 0.4 (5) 1073 ± 182 24.9 ± 7.4* (9) 
0.1 406 ± 237'~ 0.6 ± 0.4 (5) 545 ± 203'~ 13.0 ± 7.5 (9) 
8-0H-DPAT or vehicle were administered immediately before the start of the 
experiment. 
* : P < 0.05 vs vehicle (Kruskal-Wallis ANOVA followed by Mann-Whitney U 
test). RI schedule: amount of lever pressings/30 minutes during the random 
interval schedule. FR 1 schedule: amount of lever pressings/12 minutes during 
the fixed ratio 1 schedule. (Data are means± s.e.m.) 
Table 2 
Effect of PCPA on conflict behaviour and extinction of conflict behaviour 
Conflict behaviour Extinction of conflict behaviour 
PCPA 
Dose RI FR 1 RI FR 1 
(mg/kg) schedule schedule n schedule schedule n 
0.0 1283 ± 126 3.2 ± 0.6 (6) 1310 ± 194 1.6 ± 0.8 (8) 
200.0 1216 ± 74 3.5 ± 0.9 (6) 1484 ± 296 23.9 ± 6.5* (8) 
300.0 1142 ± 150 6.3 ± 1.7 (6) 962 ± 250 57.5 ± 16. o'~ (8) 
PCPA or vehicle were administered 17 hours before the start of the 
experiments. 
* : P < 0.05 vs vehicle (Kruskal-Wallis ANOVA followed by Mann-Whitney U 
test) . RI schedule: amount of lever pressings/30 minutes during the random 
interval schedule. FR 1 schedule: amount of lever pressings/12 minutes during 
the fixed ratio 1 schedule. (Data are means ± s.e.m.) 
Administration of graded doses of ICS 205-930, a 5HT3 antagonist, was without 
effect in both paradigms (Table 3). 
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Table 3 
Effect of ICS 205-930 on conflict behaviour and extinction of conflict 
behaviour 
Conflict behaviour Extinction of conflict behaviour 
ICS 205-930 
Dose RI FRl RI FR 1 
(mg/kg) schedule schedule n schedule schedule n 
0.0 1376 ± 205 2.4 ± 0.8 (5) 1106 ± 191 2.2 ± 0.8 (9) 
0.0001 1211 ± 220 1.2 ± 0.4 (5) 1147 ± 157 4.6 ± 4.3 (7) 
0.0005 1082 ± 226 1.5 ± 0.7 (4) 1256 ± 242 0.4 ± 0.2 (7) 
0.0025 648 ± 174 2.0 ± 0.7 (5) 1521 ± 126 2.5 ± 1.0 (6) 
0.0125 1093 ± 282 1.8 ± 0.7 (5) 1256 ± 194 12.5 ± 10.2 (6) 
0.0625 1309 ± 156 0.8 ± 0.4 (5) 
ICS 205-930 or vehicle were admnistered 20 minutes before the start of the 
experiments. 
RI schedule: amount of lever pressings/30 minutes during the random interval 
schedule. FR 1 schedule: amount of lever pressings/12 minutes during the fixed 
ratio l schedule. (Data are means ± s.e.m.) 
Administration of propranolol, a non-specific 5-HT1 type receptor blocker and 
a ~-adrenoceptor antagonist led to an enhanced extinction of conflict 
behaviour without affecting conflict behaviour itself (Table 4). When using 
doses of 20 or 40 mg/kg, the number of responses during the random interval 
schedule was decreased. After administration of 40 mg/kg the number of 
responses during the FRl schedule was lower as compared with the effect of 20 
mg/kg. Observation of the behaviour of the propranolol treated rats did not 
indicate that the animals were sedated. 
Table 4 
The effect of propranolol on conflict behaviour and extinction of conflict 
behaviour 
Conflict behaviour Extinction of conflict behaviour 
Propanolol 
Dose RI FRl RI FR 1 
(mg/kg) schedule schedule n schedule schedule n 
0.0 1469 ± 294 5.8 ± 1.2 (5) 1711 ± 194 3.2 ± 1.7 (6) 
5.0 1230 ± 139 6.6 ± 0.9 (5) 1041 ± 246 27.3 ± 11.6 (6) 
10.0 1041 ± 184 4.8 ± 0.9 (5) 911 ± 204 23.7 ± 9.2 (7) 
20.0 595 ± 171 8.6 ± 2.9 (5) 698 ± 128* 64.9 ± 15 .o·~c (7) 
40.0 755 ± 183 5.2 ± 1.4 (5) 581 ± 232">'< 31.0 ± 10.9 (6) 
Propranolol or vehicle were administered 20 minutes before the start of the 
experiments. 
* : P < 0.05 vs vehicle (Kruskal-Wallis ANOVA followed by Mann-Whitney U 
test). RI schedule: amount of lever pressings/30 minutes during the random 
interval schedule. FR l schedule: amount of lever pressings/12 minutes during 
the fixed ratio l schedule. (Data are means ± s.e.m.) 
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In order to investigate whether the ~1/~2-adrenoceptor blocking property of 
propranolol might be responsible for the enhancement of extinction of conflict 
behaviour, the selective ~1-adrenoceptor antagonist metoprolol and the 
selective ~2-adrenoceptor antagonist butoxamine were tested. Both drugs were 
used in dose ranges which are known to block central ~-adrenoceptors (Handley 
and Singh 1986). While butoxamine was not effective, metoprolol did induce a 
small increase in the number of responses using a dose of 4 mg/kg, but due to 
the large variation, statistical significance was not reached in these 
experiments. Metoprolol decreased the level of responding slightly during the 
random interval schedule (Table 5). 
Table 5 
The effect of butoxamine and metoprolol on conflict behaviour and extinction 
of conflict behaviour 
Extinction of conflict behaviour. 
Dose RI FR 1 
(mg/kg) schedule schedule n 
Butoxamine 
0.0 1747 ± 184 6.1 ± 3.1 (8) 
5.0 1750 ± 214 11.1 ± 6.6 (8) 
10.0 1625 ± 278 9.5 ± 4.0 (8) 
Metoprolol 
0.0 1786 ± 66 6.3 ± 2.6 (9) 
2.0 1470 ± 133'< 14.2 ± 6.2 (9) 
4.0 1210 ± 160'< 24.6 ± 12.4 (9) 
8.0 1411 ± 184 8.2 ± 3.6 (9) 
Butoxamine, metoprolol or vehicle were administered 20 minutes before the 
start of the experiments. 
* : P < 0.05 vs vehicle (Kruskal-Wallis ANOVA followed by Mann-Whitney U 
test) . RI schedule: amount of lever pressings/30 minutes during the random 
interval schedule. FR 1 schedule: amount of lever pressings/12 minutes during 
the fixed ratio 1 schedule. (Data are means ± s.e.m.) 
Pretreatment of the rats with 20 or 40 mg/kg propranolol showed an overall 
tendency to decrease 5HT behaviour evoked by 1.0 mg/kg 8-0H-DPAT (Table 6) but 
statistical significance was only reached for piano-playing and head weaving 
when using the dose of 40 mg/kg. 
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Table 6 
The effect of propranolol on the 8-0H-DPAT -induced 5HT behaviour 
dose piano- head flat body- hind limb 
mg/kg playing weaving posture abduction 
8-0H-DPAT 1.0 2.2 ± 0.9 15.3 ± 2.4 5.5 ± 1.4 6.5 ± 0.9 
8-0H-DPAT/propr 1. 0/20.0 1.3 ± 0.4 17.2 ± 3.2 4.2 ± 1.1 5.7 ± 0.8 
8-0H-DPAT/propr 1. 0/40.0 0.2 ± 0. 2>1: 2.8 ± 0. 5>1: 3.8 ± 1.1 3.0 ± 1.1 
5HT behavioural symptoms (piano playing, head weaving, flat body posture and 
abducted hind limbs). Sum of scores over 6,12,18, 24 and 30 minutes after 
injection of 1.0 mg/kg 8-0H-DPAT. Propranolol or vehicle were injected 25 
minutes before administration of 8-0H-DPAT. 
*: P < 0.05 vs 8-0H-DPAT alone (Kruskal-Wallis ANOVA followed by Mann-Whitney 
U test). Data are means± s.e.m., n = 6. 
In order to investigate whether baclofen and 8-0H-DPAT were still able to 
enhance the extinction of conflict behaviour after impairment of the 
serotonergic system, one active dose of each compound was administered to rats 
pretreated with 200 mg/kg PCPA. As shown in table 7 administration of baclofen 
or 8-0H-DPAT to rats pretreated with PCPA did not further increase the 
enhanced extinction caused by the pretreatment. 
Table 7 
The effect of baclofen or 8-0H-DPAT on extinction of conflict behaviour after 
pretreatment with PCPA 
Extinction of conflict behaviour. 
Dose RI FRl 
(mg/kg) schedule schedule n 
Vehicle pretreated 17 hours before experiment: 
0.0 1272 ± 179 1.7 ± 0.7 (6) 
Baclofen 2.0 975 ± 151 33.8 ± 12.0* (6) 
8-0H-DPAT 0.03 881 ± 168 34.3 ± 8.3* (6) 
PCPA 200 mg/kg pretreated 17 hours before experiment: 
0.0 1218 ± 341 26.2 ± 7.3'" (6) 
Baclofen 2.0 702 ± 195 20.7 ± 7. 9'" (6) 
8-0H-DPAT 0.03 1076 254 * (6) ± 32.2 ± 18.0 
The rats were pretreated with PCPA or vehicle 17 hours before the experiments. 
The animals were subsequently injected with baclofen or vehicle 20 minutes- or 
with 8-0H-DPAT or vehicle immediately before- the start of the experiments. 
* : P < 0.05 vs vehicle pretreated vehicle (Kruskal-Wallis ANOVA followed by 
Mann-Whitney U test). RI schedule: amount of lever pressings/30 minutes during 
the random interval schedule. FR 1 schedule: amount of lever pressings/12 
minutes during the fixed ratio 1 schedule. (Data are means ± s.e.m.) 
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Discussion 
The present results indicate that low doses of 8-0H-DPAT, a 5-HTlA agonist 
(Middlemiss and Fozard 1983), enhanced the extinction of conflict behaviour 
without affecting the conflict behaviour itself, an effect shared with the 
GABAB agonist baclofen (Ketelaars et al. 1988). In fact it is not unlikely 
that the effect of baclofen occurs via an impairment of the activity of the 
serotonergic system. An impairment of the 5-HT system has been suggested to be 
responsible for the anxiolytic effects in certain animal models (see Iversen 
1984; Chopin and Briley 1987). 
A functional decrease in the activity of the 5-HT system can be accomplished 
in three ways. 1. A blockade of the 5 -HT biosynthesis; 2. activation of 
autoreceptors located on 5-HT neurons and 3. postsynaptic 5-HT antagonism. The 
present results show that PCPA, an inhibitor of tryptophan hydroxylase, 
increased the extinction of conflict behaviour without affecting conflict 
behaviour itself and thus caused an effect as has been described previously 
for baclofen (Ketelaars et al. 1988). Although the lack of effect of PCPA on 
conflict behaviour is in agreement with results of Blakely and Parker (1973) 
and those by Cook and Sepinwall (1975), others have reported a weak effect 
(Kilts et al. 1982) or marked effects on conflict behaviour (Geller and Blum 
1970; Robichaud and Sledge 1969; Stein et al. 1973; Tye et al. 1979; Engel et 
al. 1986). Also anti-conflict effects of 8-0H-DPAT have been reported (Engel 
et al. 1986; Carli and Samanin 1988). However, other reports on the anti-
conflict effect of 5HT1A receptor agonists are less consistent (Deacon and 
Gardner 1986; Chopin and Briley 1987). It is postulated that the effect of 8-
0H-DPAT is dependent on the state of arousal of the rat and thus on the type 
of animal model of anxiety used (Carli and Samanin 1988). These differences in 
anti-conflict effect, obtained after pretreatment of the rats with PCPA or 
after treatment with 8-0H-DPAT, may be explained by differences in the 
training procedure, schedules or degree of suppression. In the present 
experiments, the use of rats trained on a conflict schedule resulting in 0-5 
responses during the whole session (6 times 2 min sessions alternated by 6 
times a random interval schedule, see Method section) can clearly 
differentiate between benzodiazepines (Ketelaars et al. 1988 and Ketelaars and 
Bruinvels 1989) on one hand and drugs that impair serotonergic function on the 
other by measuring both the anti-conflict effect and the extinction of 
conflict behaviour. The effect of low doses of 8-0H-DPAT which enhanced 
extinction of conflict behaviour without affecting conflict behaviour itself, 
may also be the result of an impaired serotonergic function by activation of 
5-HTlA autoreceptors decreasing impulse-flow-induced release of serotonin 
(Dourish et al. 1986), while the use of higher doses of 8-0H-DPAT may activate 
also postsynaptically located 5-HTlA receptors evoking the 5-HT syndrom 
(Goodwin et al. 1987; Tricklebank et al. 1984). The involvement of the 5-HT 
system in enhancing extinction of conflict behaviour was further supported by 
the effect of propranolol, a non-specific 5-HTl receptor antagonist 
(Middlemiss et al. 1977; Green et al. 1983; Nahorski and Willcocks 1983), 
which also increased the extinction of conflict behaviour without affecting 
conflict behaviour by blocking postsynaptically located 5-HTl receptors. 
Although it could not be concluded whether the antagonism of 5-HTlA or 5-HTlB 
receptors or both receptor types are responsible for the effect of 
propranolol, the doses of propranolol used seem at least to be appropiate for 
blocking postsynaptic 5-HTlA receptors since these doses were capable to 
antagonize the 5-HT syndrome induced by a high dose (1 mg/kg) of 8-0H-DPAT. 
That the ~1 and ~2 blocking properties were not responsible for the effect of 
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propranolol was shown by the lack of effect of the specific ~1 and ~2 
antagonists metoprolol and butoxamin respectively. Both drugs were 
administered in doses shown to be behaviourally active (Handley and Singh 
1986). The effect of propranolol to antagonize the 5-HT syndrome is in 
agreement with results obtained by Tricklebank et al. (1984) who used 8-0H-
DPAT and with Green and Graham-Smith (1976) who used L-tryptophan combined 
with tranylcypromine to induce the 5-HT syndrome. 
The lack of effect of the 5-HT3 antagonist ICS 205-930 on extinction of 
conflict behaviour indicated that the enhancement of extinction may be 
specifically mediated by blockade of 5-HT1 receptors since, as has been 
previously shown, also 5-HT2 receptor antagonists were ineffective (Ketelaars 
et al. 1988; Ketelaars and Bruinvels 1989). 
Since the effect of 8-0H-DPAT, PCPA or propranolol is identical to that 
obtained with baclofen (Ketelaars et al. 1988), it is not unlikely that the 
latter exerts its effect via the 5-HT neuronal system. Indeed it has been 
shown that baclofen decreases 5-HT activity by inhibition of 5-HT release 
(Schlicker et al. 1984; Gray and Green 1987). Supporting evidence for an 
intermediary role of the 5-HT system in the effect of baclofen on extinction 
of conflict behaviour was obtained by pretreating rats with PCPA. In these 
rats both baclofen and 8-0H-DPAT were without effect. 
In conclusion, the present results show that impairment of the 5-HT neuronal 
activity by three different procedures increased extinction of conflict 
behaviour without affecting conflict behaviour itself. The latter is in 
contrast to the action of benzodiazepines (Ketelaars et al. 1988). A 
combination of increased extinction of conflict behaviour and a lack of effect 
on conflict behaviour itself has also been shown to occur after administration 
of baclofen to rats (Ketelaars et al. 1988). This effect did not occur in rats 
depleted of 5-HT by pretreatment with PCPA, suggesting that the effect of 
baclofen could only be evoked through an intact 5-HT system. 
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BACLOFEN-INDUCED EXTINCTION OF CONFLICT BEHAVIOUR, RELATIONSHIP 
WITH THE GABAERGIC AND SEROTONERGIC SYSTEM. 
C.E.J. Ketelaars and J. Bruinvels. 
submitted for publication 
Summary 
The mechanism behind the effect of the baclofen-induced extinction of conflict 
behaviour might be mediated via two mechanisms; an indirect GABAA receptor 
activation or an impairment of serotonergic system function. The present 
results showed that bicuculline antagonized the effect of oxazepam on 
extinction, but the GABAA antagonist did not counteract the baclofen-induced 
extinction. The selective serotonine (5-HT) reuptake inhibitor fluvoxamine 
counteracted the effect of both oxazepam and baclofen on extinction, but not 
the 8-0H-DPAT-induced extinction. Finally, the effect of long-term 
administration of fluvoxamine and its interaction with the effect of baclofen 
and 8-0H-DPAT is described. The present results support the suggestion that 
the effect of baclofen on extinction of conflict behaviour is mediated via an 
impaired serotonergic system, and not via an indirect effect via the 
GABAA/benzodiazepine receptor chloride channel complex. The results obtained 
during and after long-term fluvoxamine administration seem to agree with the 
suggestion that anti-depressants induce a GABAB receptor upregulation, but do 
not support the reports that these compounds induce a desensitization of pre-
and postsynaptic 5-HTlA receptors. 
Introduction 
GABA receptors in rat brain are subdivided into two subtypes depending on 
their affinity for the GABA receptor antagonist bicuculline or for the 
GABA-analog baclofen (~-(p-chlorophenyl)-GABA). GABAA receptors are sensitive 
to bicuculline and not to baclofen, while GABAB receptors are sensitive to 
baclofen and not to bicuculline (Hill and Bowery (1981), Bowery et al. 
(1983)). It is assumed that the anxiolytic effects of the benzodiazepines are 
mediated via the GABAA/benzodiazepine receptor chloride ionophore complex. 
Thus it has been reported that GABAA antagonists antagonize the action of 
benzodiazepines in rat conflict models, but the reports are equivocal and no 
consensus about the exact mode of action has been reached (Costa et al. 
(1975), Sepinwall and Cook (1980), Sanger (1985)). As shown previously, 
benzodiazepines and baclofen both enhance extinction of conflict behaviour 
(Ketelaars et al. 1988). On the level of receptor binding no interrelationship 
between benzodiazepine and GABAB receptors could be shown (Majewska and Chuang 
(1984), Karobath and Sperk (1979), Ketelaars et al. (1988)). However, it can 
not be ruled out that the effect of baclofen on extinction of conflict 
behaviour is mediated in vivo via GABAA receptors. 
baclofen may exert its effect via presynaptic 
neurones, resulting in an enhanced release of GABA 
Roberts et al. (1978)). 
It is still possible that 
activation of GABA-ergic 
(Kerwin and Pycock (1978), 
Another possibility for a mediator responsible for the effect of baclofen on 
extinction may be decrease of activity of the serotonergic system. It has been 
shown that a reduction in 5-HT neurotransmission has anxiolytic effects in 
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animal models for anxiety, while the reverse is true for a stimulation of the 
5-HT system (review: Chopin and Briley (1987)). The 5-HT theory (i.e. a 
decreased 5 -HT activity) related to the anti-conflict effect of 
benzodiazepines was first postulated by the group of Wise and Stein (1972 and 
1973). It has also been shown by Sclicker et al. (1984) and Gray and Green 
(1987a) that baclofen decreases the release of 5-HT in a synaptosomal fraction 
obtained from rat cortical tissue. Moreover, in a previous study, it has been 
shown that impairment of the 5-HT function by PCPA, 8-0H-DPAT or propranolol 
(inhibition of 5-HT biosynthesis, inhibition of 5-HT release or post-synaptic 
5-HTl antagonism respectively) enhances extinction of conflict behaviour 
(Ketelaars and Bruinvels, submitted). 
In clinical literature, it is reported that baclofen (Pepplinkhuizen and 
Bruinvels (1978)), Breslow et al. (1989)) and the selective 5-HT reuptake 
inhibitor fluvoxamine (Den Boer et al. (1987)) both possess anti-panic 
properties. Several anti-depressants, which also have anti-panic activity, 
increase the Bmax of GABAB receptors after long-term administration via a 
still unknown mechanism, but it is shown that the latter mechanism is not 
caused by a decreased GABA concentration in the synaptic cleft (Pile and Lloyd 
(1984), Suzdak and Gianutsos (1986)). It has been suggested that anti-
depressants may exert their anti-panic effect via GABAB receptor upregulation 
and function (Breslow et al. (1989)). 
The aim of the present experiments was twofold: 1/ To investigate further the 
possibilities that the effect of baclofen on extinction of conflict behaviour 
is mediated by an enhanced GABAA receptor activation or by an impairment of 5-
HT function (or both). Therefore, the effect of the GABAA antagonist 
bicuculline and the effect of the 5-HT reuptake inhibitor fluvoxamine on the 
baclofen-induced increase in extinction of conflict behaviour were 
investigated. Oxazepam was used as an additional control group in the 
experiments with bicuculline. 2/ The second aim was to see whether long-term 
administration of fluvoxamine was active in enhancing extinction of conflict 
behaviour. It is shown by several groups that long-term administration of 
anti-depressants increases GABAB receptor number and function, (Pile and Lloyd 
(1984), Suzdak and Gianutsos (1986), Gray and Green (1987), Gray et al. 
(1987)) and decreases pre- and postsynaptic 5HT1A receptor function (Goodwin 
et al. (1987), Stolz et al. (1983)) during or after 2 to 3 weeks of treatment. 
In order to find out whether these observations would also agree with the 
anxiolytic effects induced by GABAB- and 5-HTlA- receptor activation, the 
effect of long-term administration of fluvoxamine alone and its effect on the 
baclofen- and 8-0H-DPAT-induced extinction was investigated. 
Methods 
Extinction of conflict behaviour. In order to study extinction of conflict 
behaviour the Geller-Seifter test (Geller and Seifter 1960) was used as 
described previously (Ketelaars et al. 1988). In brief: After being deprived 
of water for 16 hours, male Wistar rats (starting weight: 70 - 90 g; after 
training was completed: 250 - 350 g) were placed in an experimental chamber 
measuring 20 x 20 x 20 em, containing a response lever, milk delivery 
apparatus, an electrifiable grid floor and a stimulus light. The rats were 
trained to press a lever in order to obtain milk and were subsequently trained 
once a day for a duration of 42 minutes. Within these training (and test) 
periods, two schedules were used in alternation. During 5 minutes a 5 % random 
interval (RI) schedule was offered. This schedule was alternated with 2 
minutes of a fixed ratio 1 (FR 1) schedule. A steady light signal during the 
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FR 1 schedule served as the discriminative stimulus. This combination of RI 
and FR 1 schedules was presented 6 times to each rat per session. After 
stabilization of performance, response-contingent foot shock was given during 
the FR 1 periods. Shock levels (100-160 V, 2 - 3.3 rnA) were individually 
adjusted until cumulative lever pressings during the FR 1 periods were below 5 
per 12 minutes, which represents about 5 % of the number of lever pressings 
before foot shock was applied. Drug effects on extinction of conflict 
behaviour were measured on the third day, always after 2 days of training in 
order to achieve a stable "base line" level of conflict behaviour. On the test 
days, foot shock was turned off. During the 2 days before the test days 
training continued in the presence of foot shock, and shock levels were 
adjusted when the animals took more than 5 shocks per 12 minutes. After at 
least 20 training sessions, spontaneous extinction was non-existent in control 
rats during the trial period; i.e. these animals responded with an average of 
0 to 5 pressings per 12 minutes. 
In the extinction test with the low level of conflict behaviour, training was 
stopped and test were started when spontaneous extinction was at the level of 
50% (±50 lever presses per 12 minutes). Six groups of 12 rats and two groups 
of 18 rats were used. Five groups of 12 rats were used in the extinction test 
with a high level of conflict and one group of 12 rats was used in the 
extinction test with a low level of conflict. The two groups of 18 rats were 
used in the extinction tests with long-term fluvoxamine or its vehicle 
administration. Vehicle and different doses of each drug were administered to 
each rat of a group using a latin square design. The effects of drugs were 
tested once a week to allow for a sufficiently long wash out period. During 
the training, before the extinction experiments were performed, the chronic 
administration of fluvoxamine caused no need for extra adjustments of shock 
levels. 
Drugs: 
The doses of baclofen, oxazepam and 8-0H-DPAT were active doses taken from 
previously established dose-response curves (Ketelaars et al. (1988), 
Ketelaars and Bruinvels, submitted). As specified later in this section, 
bicuculline was administered in a dose of 0. 5 mgjkg twice; 20 minutes and 
immediately before the start of the experiments. As indicated in the result 
section, some rats showed signs of 5-HT behaviour when the highest dose (20 
mg/kg) of fluvoxamine was used. Since this might disturb performance of the 
rats, a dose of 10 mg/kg was used in the acute experiments. All drugs used 
were administered intraperitoneally in a volume of 1 ml/kg. Baclofen was 
dissolved in saline and injected 20 minutes before the behavioural experiments 
started. Oxazepam was administered 20 minutes before the experiment as a 
sonicated suspension in distilled water to which a drop of Tween 80 had been 
added. Bicuculline was dissolved in acidified saline (pH 4.0). A pilot study 
showed that higher doses than 0. 5 mg/kg could not be used since the rats 
started to show convulsions. In order to prevent this seizure activity and to 
prolong the duration of the GABAA antagonistic action, bicuculline was 
injected twice in a dose of 0.5 mg/kg. The first dose was administered 20 
minutes before and the second dose immediately before the start of the 
experiments. 8-0H-DPAT was dissolved in saline and injected immediately before 
the experiments started. Fluvoxamine was dissolved in distilled water and 
injected 30 minutes before the start of the experiments. Every control rat 
received the appopriate vehicle. Separate injections of drugs were given in 
the combination experiments. For the long-term administration of fluvoxamine 
(14 days), Alzet mini pumps were used. In these experiments, fluvoxamine was 
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dissolved in DMSO/distilled water (1:1 vjv). Fluvoxamine was dissolved in such 
a concentration that the mini pumps delivered a dose of 20 mg/kgjday to the 
rats. Mini pumps with vehicle were implanted in control rats. Oxazepam was 
kindly donated by Wyeth, baclofen was kindly donated by Ciba-Geigy. Alzet mini 
pumps and fluvoxamine were kindly donated by Duphar. 8-0H-DPAT was obtained 
from RBI. Bicuculline was obtained from Sigma. 
~s~t~a~t~i~s~t~i~c~a~l~~a~n~a~ly~s~i~s~. Data were analysed using non-parametric (Kruskal 
Wallis) one way analysis of variance (ANOVA) followed by the Mann-Whitney U 
test. 
Results 
As shown in Table lA, bicuculline antagonized the effect of oxazepam on 
extinction of conflict behaviour. Both drugs given alone or in combination did 
not affect the level of responding during the RI schedule. The same dose-
regimen of bicuculline was used in the extinction experiments using baclofen 
instead of oxazepam. In contrast to the effect of oxazepam, the effect of 
baclofen on extinction of conflict behaviour was not antagonized by 
bicuculline (Table lB). A small decrease in responses during the RI schedule 
occurred after baclofen administration. This effect was also not affected by 
bicuculline. Like in the experiments with oxazepam, bicuculline itself did not 
affect the number of responses during both schedules. 
Table 1 Effects of bicuculline on oxazepam- and baclofen-induced extinction 
of conflict behaviour. 
Extinction of conflict behaviour. 
Dose RI FRl n 
(mg/kg) schedule schedule 
A 
Control 1372 ± 223 3.9 ± 1.7 (10) 
Oxazepam 10.0 1335 ± 242 72.8 ± 23.2$ (10) 
Oxazjbic,~ 10.0/0.5 1631 ± 242 14.2 ± 5.2 (9) 
Bicuculline * 0.5 1127 ± 286 6.6 3.5 (9) ± 
B 
Control 1774 ± 189 4.3 ± 1.8 (8) 
Baclofen 2.0 1029 ± 191,~ 37.9 ± 12.2* (8) 
Bacjbic * 2.0/0.5 1088 ± 291,~ 47.7 ± 15.6* (6) 
Bicuculline * 0.5 1685 156 13.2 ± 8.5 (6) ± 
$: P < 0.05 vs control and vs oxazjbic (Kruskal-Wallis ANOVA followed by Mann-
Whitney U test). *: P < 0.05 vs control (Kruskal-Wallis ANOVA followed by 
Mann-Whitney U test). Cumulative level of responding per session during random 
interval (RI) and fixed ratio 1 (FR 1) schedule per 30 and 12 min 
respectively. Data are mean± s.e.m. *: Bicuculline was administered twice as 
described in the method section. 
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Administration of fluvoxamine did not affect responding in the FR 1 or RI 
schedule (Table 2A). Using the highest dose (20 mg/kg), some mild signs of 5HT 
behaviour were observed (flat body posture, abducted hindlimbs). Since 
fluvoxamine administration will increase serotonergic activity, an anxiogenic 
effect may occur resulting in a decreased extinction. Therefore a lower level 
of punishment (50 % decrease of preexisting level of responding) was used. 
However, as shown in Table 2B, also under these circumstances fluvoxamine 
administration was without effect. 
The effect of fluvoxamine on the baclofen-, 8-0H-DPAT- and oxazepam- induced 
extinction was investigated. As shown in Table 3A, fluvoxamine (10 mg/kg) 
counteracted the oxazepam- and baclofen-induced enhancement of extinction of 
conflict behaviour, while fluvoxamine did not affect the action of 8-0H-DPAT 
on extinction (Table 3B). The animals treated with baclofen in combination 
with fluvoxamine were sedated. 
Table 2 Effect of fluvoxamine on extinction of conflict behaviour. 
Extinction of conflict behaviour. 
Dose RI FRl 
(mg/kg) schedule schedule n 
A 
Control 1402 ± 186 6.6 ± 4.2 (9) 
Fluvoxamine 5.0 1715 ± 312 6.4 ± 2.3 (8) 
10.0 1275 ± 379 7.4 ± 5.6 (7) 
20.0 1558 ± 238 16.9 ± 10.2 (8) 
B 
Control 1019 ± 127 45.6 ± 8.2 (12) 
Fluvoxamine 10.0 1110 ± 167 37.5 ± 8.0 (12) 
20.0 815 ± 98 50.8 ± 7.6 (12) 
Cumulative level of responding per session during random interval (RI) and 
fixed ratio 1 (FR 1) schedule per 30 and 12 min respectively. Data are mean ± 
s.e.m .. In order to allow the possibility of a decrease in extinction, a lower 
conflict level was realized by training the animals to a 50% decrease from 
pretraining FR 1 responding (see method section). 
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Table 3 Effect of fluvoxamine on the baclofen-, oxazepam- and 8-0H-DPAT 
-induced extinction of conflict behaviour. 
A 
Control 
Baclofen 
Oxazepam 
Fluvoxamine 
Flujbaclofen 
Flu/oxazepam 
B 
Control 
8-0H-DPAT 
Fluvoxamine 
Flu/8-0H-DPAT 
Dose 
(mg/kg) 
1.5 
2.0 
2.5 
10.0 
10.0 
10.0/1.5 
10.0/2.0 
10.0/10.0 
0.03 
10.0 
10.0/0.03 
Extinction of conflict behaviour. 
RI 
schedule 
1361 ± 318 
1276 ± 277 
1088 ± 242 
431 ± 222'" 
1456 ± 398 
1435 ± 391 
461 ± 172+ 
68 ± 49+ 
1532 ± 487 
1520 ± 259 
1165 ± 201 
1037 ± 199 
1063 ± 226 
FR 1 
schedule 
2.5 ± 2.1 
34.3 ± 14.1$ 
26.0 ± 10.7$ 
27.0 ± 10.4* 
77.3 ± 36. g$ 
5.7 ± 3.7 
7.3 ± 6.9 
2.2 ± 2.2 
7.2 ± 6.4 
1.5 ± 0.4 
55. 1 ± 14. g>'< 
5.8 ± 3.3 
69.7 ± 17.9'" 
n 
(6) 
(6) 
(6) 
(6) 
(6) 
(6) 
(6) 
(5) 
(6) 
(10) 
(10) 
(10) 
(9) 
*: P < 0.05 vs control $: P < 0.05 vs control and vs fluvoxaminejoxazepam or 
fluvoxaminejbaclofen +: P < 0. 05 vs control and fluvoxamine and baclofen 
alone. (Kruskal-Wallis ANOVA followed by Mann-Whitney U test). Cumulative 
level of responding per session during random interval (RI) and fixed ratio 1 
(FR 1) schedule per 30 and 12 min respectively. Data are mean ± s.e.m. 
As shown in fig lA, administration of 20 mg/kg fluvoxamine 17 hours before 
baclofen or 8-0H-DPAT did not affect the action of the latter two drugs 
significantly. It must be noted however, that the mean number of responses of 
the baclofen-induced extinction was nearly doubled. The effect of 
administration of fluvoxamine (20 mg/kg/day) by mini-pump alone and its effect 
on the baclofen- and 8-0H-DPAT-induced extinction is also described in figure 
lA and B. The number of responses during the RI schedule tended to be lower in 
the fluvoxamine treated group during the whole experiment. In analogy with the 
acute experiments, the baclofen-induced decrease in responding during the RI 
schedule was augmented in the fluvoxamine treated group of rats. In contrast, 
but again in analogy with the results shown in Table 3, fluvoxamine tended to 
counteract the effect of baclofen on extinction. On the 16th day, i.e. two 
days after terminating the administration of fluvoxamine, the extinction was 
enhanced in the fluvoxamine treated control group. The baclofen- induced 
extinction tended to be enhanced. The sedative effect of baclofen during the 
RI schedule was significantly increased. The effect of 8-0H-DPAT on extinction 
was not affected by pretreatment of fluvoxamine, while in this group the 
number of responses during the RI schedule was decreased in the fluvoxamine 
pretreated group. On the 19th day, the fifth day after terminating the 
fluvoxamine administration, the effect of fluvoxamine on extinction in the 
control group had disappeared. The enhanced sedative effect of baclofen, as 
shown by the decrease in number of responses during the RI schedule, was still 
present, as well as the decreased number of responses in the RI schedule in 
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the 8-0H-DPAT group. The tendency for an enhanced baclofen -induced extinction 
was also still present. The responses during the RI schedule seemed to 
normalize on the last test day, 2 weeks after terminating administration. 
FIGURE 1A. 
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Cumulative level of responding per session during Fixed Ratio 1 (FR 1) 
schedule per 12 minutes. Data are mean, s.e.m. was in the similar range as in 
Table 1 to 3. 
*: P < 0.05 vs control within same mini-pump administered treatment. 
#: P < 0.05 vs same drug/vehicle mini-pump treated. 
Statistical significance is after Kruskal-Wallis ANOVA followed by Mann-
Whitney U test. 
73 
FIGURE lB. 
fig. 18 
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-1: Fluvoxamine treatment was given 1 day before treatment with baclofen 
or 8-0H-DPAT 
Cumulative level of responding per session during random interval (RI) 
schedule per 30 minutes. Data are mean, s.e.m. was in the similar range as in 
Table 1 to 3. 
*: P < 0.05 vs control within same mini-pump administered treatment. 
#: P < 0.05 vs same drug/vehicle mini-pump treated. 
Statistical significance is after Kruskal-Wallis ANOVA followed by Mann-
Whitney U test. 
Discussion 
The assumption that the oxazepam- or baclofen- induced extinction of conflict 
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behaviour in rats is mediated via the GABAA system, (oxazepam via its well 
known GABAA facilitating effect and baclofen indirectly by causing release of 
GABA (Kerwin and Pycock (1978), Roberts et al. (1978)) seems valid for 
oxazepam, but could not be proven for baclofen. The present experiments 
clearly showed that.the baclofen-induced enhancement of extinction of conflict 
behaviour could not be antagonized by the GABAA antagonist bicuculline, while 
the increase in extinction induced by oxazepam could be antagonized by this 
GABAA antagonist. Therefore, GABAA receptor activation can be excluded as a 
common pathway for oxazepam and baclofen in vivo, a conclusion which is 
supported by previous results showing that baclofen administration to rats 
does not affect GABA release as measured by binding properties of 
benzodiazepines in vitro (Ketelaars et al. (1988)). The action of bicuculline 
to antagonize the anxiolytic effect of benzodiazepines has been shown 
previously (Quintero et al. (1985), Zakusov et al. (1977), Scheel-Kruger and 
Petersen (1982), Velluci and Webster (1984)). However, some of these reports 
are open to criticism, e.g. due to an inadequate description of the method 
used (Zakusov et al. (1977)), or the occurrance of seizure activity in the 
rats treated with bicuculline (Quintero et al. (1985)). Besides, negative 
results on the anxiolytic effect of diazepam after co-administration with 
bicuculline have also been reported (Liljequist & Engel 1984). The present 
experiments rule out the possibility that baclofen in vivo indirectly 
activates GABAA receptors and so mediates its effect on extinction. 
This leads to a second possibility, namely that baclofen enhances the 
extinction of conflict behaviour by impairment of serotonergic activity. This 
would be supported by the fact that inhibition of 5-HT synthesis by PCPA also 
results in an increase of extinction and prevented a further increase by 
baclofen and 8-0H-DPAT (Ketelaars and Bruinvels, submitted). It was therefore 
decided to use the specific 5-HT reuptake inhibitor fluvoxamine to see whether 
an increased availability of 5-HT could counteract the effect of baclofen. 
Since it is has been suggested that the effects of 8-0H-DPAT and 
benzodiazepines in animal models for anxiety are mediated by a decrease of 5-
HT function (Traber and Glaser (1987), Wise et al. (1972), Stein et al. 
(1973)), 8-0H-DPAT and oxazepam were taken as additional control groups in the 
experiments with baclofen and fluvoxamine. Fluvoxamine itself was without 
effect on the extinction of conflict behaviour. Also when a lower level of 
conflict was used, to detect an anxiogenic action, fluvoxamine was 
ineffective. However, administration of fluvoxamine counteracted the effect on 
extinction of both baclofen and oxazepam, an effect which can not be ascribed 
to a sedative action since the RI response obtained after the concomitant 
administration of fluvoxamine and 1.5 mg/kg baclofen is comparable to the RI 
response obtained after 2. 5 mg/kg baclofen. Thus it may be concluded that 
administration of fluvoxamine counteracted the increased extinction induced by 
baclofen or oxazepam independent of the presence of sedation. This effect may 
be caused by a increased accumulation of 5-HT in the synaptic cleft resulting 
in an augmented interaction with 5-HT receptors. Although this agrees very 
well with the proposed anxiogenic effect of 5-HT in animal models for anxiety 
(Chopin and Briley (1987), Broekkamp et al. (1989)), and may thus explain this 
action of fluvoxamine, the failure to detect in the present experiments an 
anxiogenic effect of this drug when administered alone does not support this 
explanation. However, this may depend on the model used, since anxiogenic 
responses in animal models of anxiety have been reported after administration 
of several selective 5-HT reuptake inhibitors (Chopin and Briley (1987)) 
while, on the other hand, it is also shown that acute administration of 
fluvoxamine has an anxiolytic action in the defensive burying test and the 
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four plates test (Broekkamp et al (1989), Molewijk and Van der Heijden 
(1988)). 
Like baclofen the 5-HTlA agonist 8-0H-DPAT also increases extinction of 
conflict behaviour without affecting conflict behaviour itself (Ketelaars and 
Bruinvels, submitted). However, in contrast to baclofen fluvoxamine did not 
affect the 8-0H-DPAT-induced increase in extinction. This lack of effect of 
fluvoxamine was unexpected since the action of 8-0H-DPAT is ascribed to an 
activation of somatodendritic autoreceptors resulting in a decreased 5-HT 
release (Traber and Glaser (1987)). If this would be the mechanism responsible 
for the enhanced extinction by 8-0H-DPAT, fluvoxamine should have counteracted 
the effect. This lack of effect of fluvoxamine might be explained by an 
anxiolytic effect of 8-0H-DPAT mediated via postsynaptic 5-HTlA receptors. 
This would implicate that activation of postsynaptic 5-HT receptors may not 
only exert anxiogenic effects but also anxiolytic effects. This latter effect 
might be evoked by the 5-HTlA receptors which exert an inhibitory effect on 
hippocampal activity (Andrade et al. (1986), Newberry and Nicoll (1984)). A 
mixture of anxiogenic and anxiolytic postsynaptic 5-HT receptors might also 
explain the reported different effects of 5-HT reuptake inhibitors, since the 
net effect of such a drug would than be dependent on the balance of 
stimulation of various 5-HT receptors. Although a dose of 10 mg/kg fluvoxamine 
counteracted the effects of oxazepam and baclofen, another explanation for the 
lack of effect of fluvoxamine on the 8-0H-DPAT-induced extinction might be 
that a higher dose of fluvoxamine is needed to antagonize the effect of 8-0H-
DPAT. 
Several hypotheses about the mechanism behind the anxiolytic effects of anti-
depressants exist: Desensitization of postsynaptic 5HT1 receptors (Den Boer 
(1988)), an enhanced GABA(B) receptor activation (Breslow et al. (1989)) or 
downregulation of adrenoceptors (Charney and Heninger (1985)). 
The present results showed that extinction of conflict behaviour was enhanced 
on the third day after terminating long-term treatment of fluvoxamine. The 
latter effect indeed suggests an adaptive process induced by this compound and 
supports the findings of Fontana et al. (1989), who have shown an anxiolytic 
effect in an animal model after long-term treatment with an anti-depressant. 
The results obtained with baclofen after long-term administration of 
fluvoxamine, suggest the existence of GABAB receptor upregulation. Although 
the baclofen-induced extinction was counteracted during administration of 
fluvoxamine (this is in analogy with the acute experiments), it was indeed 
increased after terminating the fluvoxamine administration. Interestingly, the 
baclofen-induced extinction was of the same magnitude one day after a single 
injection of 20 mg/kg fluvoxamine. This suggests a fast process after an 
injection, but a slow process using a mini-pump. This fast process was already 
described by Pile and Lloyd (1984), since they showed a consistent tendency 
for an increased binding after one day pretreatment with anti-depressants. 
However, Gray and Green (1987) and Gray et al. (1987) did not confirm this 
result in their behavioural studies. The long-term administration of 
fluvoxamine did not affect the 8-0H-DPAT-induced extinction. This is in 
contrast with the reports of Goodwin et al. (1987), who have shown a decrease 
of pre- and postsynaptic 5HT1A receptor activation-induced effects after two 
weeks of anti-depressant treatment. Chaput et al. (1988) reported that within 
14 days of treatment with selective 5-HT reuptake inhibitors both 
somatodendritic and terminal autoreceptors were desensitized. However, this 
group reported that postsynaptic-mediated electrophysiological responses to 5-
HT were not changed. Since the effect of 8-0H-DPAT on extinction was not 
affected, the likelyhood of the earlier suggestion that the 8-0H-DPAT-induced 
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extinction may not be mediated via the presynaptic 5-HTlA autoreceptor 
increases. It is tentative to suggest that the postsynaptic 5-HTlA receptor by 
which 8-0H-DPAT may exert its effect on extinction does not desensitize after 
fluvoxamine treatment. 
The results obtained in the RI schedule deserve a separate discussion; In the 
acute and long-term experiments, combined administration of fluvoxamine and 
baclofen caused an excessive sedation of the rats. This suggests that 
fluvoxamine and baclofen interact with eachother in two opposite directions: a 
synergistic-like effect on sedation, and an antagonistic effect on extinction. 
The baclofen-induced decrease in the number of responses during the RI 
schedule was not only augmented during fluvoxamine treatment, but also after 
the termination of the fluvoxamine administration, the latter effect supports 
the suggestion of GABAB upregulation. 
The present experiments support the suggestion that baclofen enhances 
extinction via an impairment of the serotonergic system. The results obtained 
after long-term administration of fluvoxamine seem to agree with the reported 
GABAB receptor upregulation but do not support the reported pre- and 
postsynaptic 5-HTlA receptor downregulation. 
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CHAPTER VI 
GENERAL DISCUSSION 
Introduction. 
Baclofen has a beneficial effect on all components of panic disorder, i.e. 
panic attacks, anticipatory anxiety and phobic symptoms. This was shown by 
Pepplinkhuizen and Bruinvels (1978) in an open trial with 9 panic disorder 
patients (than called patients with an anxiety neurosis) which were compared 
with 10 patients diagnosed as having anxiety hysteria, neurasthenia and 
depressive neurosis with anxiety. While all panic disorder patients showed 
great improvement, no effect was shown in the control group. The drug doses 
(10 rng three times per day) used does not cause muscle relaxation. The 
efficacy of baclofen in panic disorder has also been investigated by Breslow 
et al. (1988), who used the same dose-regimen as Pepplinkhuizert and Bruinvels, 
and reported in a pilot study with 9 patients that the panic attack frequency 
and anxiety decreases during 4 weeks of treatment. The observations of 
Pepplinkhuizen and Bruinvels formed the basis for the present investigation 
into the mechanism responsible for the anxiolytic effect of baclofen. A new 
animal model for anxiety (extinction of conflict behaviour) was conceptualized 
in which baclofen might be active since baclofen is without effect in a 
conventional animal model for anxiety, the Geller-Seifter conflict test (see 
paragraph 1. 6 .1.) . However, the anxiety of a patient suffering from panic 
disorder does not resemble an actual conflict situation. After a panic attack, 
the patients tend to anticipate attacks and/or tend to avoid situations in 
which an attack might occur (resp. anticipatory anxiety and phobic avoidance). 
The idea behind the model of extinction of conflict behaviour is that passive 
avoidance, which might be defined as an inhibition of a behaviour caused by 
the memory of an aversive experience, resembles closely the human behaviour 
after panic attacks. 
Extinction of conflict behaviour. 
Extinction of conflict behaviour fulfills a number of criteria mentioned in 
paragraph 1.6., it is sensitive to low doses of oxazepam and baclofen (chapter 
II), chlordiazepoxide (unpublished observations) and 5-HT modulating drugs 
(chapter IV and V). In addition, haloperidol (chapter II) and anticholinergics 
(chapter III) are active. Baclofen does not induce an increase in drinking of 
rats while staying in their horne cage (unpublished observations), or in the 
unpunished control group of the Vogel test (chapter II). Baclofen shows 
habituation of its effect on extinction after 3 to 4 days of daily 
administration (unpublished observations). A similar finding (loss of action 
after 5 days of baclofen administration) concerning baclofen- induced 
hypothermia in mice is reported by Gray et al. (1987), and GABAB receptor 
downregulation after 14 days of baclofen administration is reported by Suzdak 
and Gianutsos (1986)). 
The behaviour of the rats during the FR 1 schedule has been observed 
frequently. Generally, the rats showed an approach-avoidance conflict, i.e. 
they approached and backed away from the lever with occasionally pushing it. 
In other words: The fear for the foot-shock was present while the foot-shock 
itself was not. Although it is not allowed to think about animal models for 
anxiety in antropornorphic terms, it is tentative to suggest that this 
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expectation of an aversive event may reflect anticipatory anxiety in man, and 
the passive avoidance behaviour of the rats may reflect phobic avoidance. 
In addition to the anxiolytic effect of baclofen in the extinction model 
and in Vogel's test (chapter II), baclofen is active in the four plate test 
(pers. conun. J. van der Heyden, Duphar BV Weesp). It has been reported by 
Allikmets and Rago (1988) that baclofen has an anxiolytic action in the 
elevated plus maze test. It is shown in a pilot study that baclofen exerted a 
strong tendency to shorten the latency for re-entering the dark compartment in 
the one-trial passive avoidance test at doses that did not affect open field 
behaviour (pers. conun. D. de Wied, Rudolf Magnus Institute Utrecht). In 
addition, baclofen tends to increase exploration in the shock probe conflict 
test (pers. comm. T.F. Meert, Janssen Research Foundation Beerse). Finally, 
Audi and Graeff (1987) reported that baclofen does not increase the threshold 
for aversive brain stimulation. In conclusion, these data indicate that 
baclofen is effective in several animal models for anxiety, this is in 
agreement with the clinically observed anxiolytic effect of this compound. 
Extinction of conflict behaviour seems a sensitive paradigm for detecting 
anxiolytic drugs. This is especially of importance concerning the 5-HT 
modulating agents, which are weakly or not active in the classical tests using 
conflict behaviour. An interesting feature is that it is now possible to 
separate drugs into two groups: Those that have both anti-confict efficacy and 
enhance extinction of conflict behaviour, and those drugs that show selective 
efficacy, i.e. only enhance extinction of conflict behaviour. These separate 
groups may reflect different anxiolytic profiles in man. 
The fact that haloperidol is active in enhancing extinction might be 
explainable by the fact that neuroleptics possess anxiolytic efficacy in man 
(paragraph 1.5.2.). Both dopamine receptor blockade and/or 5-HT receptor 
blockade (Wander et al. (1987)) might be responsible for its effect on 
extinction. The action of anti-cholinergic agents might also be due to an 
anxiolytic action (paragraph 1.5.3.). On the other hand, the effect on 
extinction might also be partly caused by a decreased ability to retrieve 
memory for aversive experiences like foot shock punishment (review: Bartus et 
al. (1987)). Since passive (or active) avoidance is based on memory for 
aversive experiences (paragraph 1.6.4.), it is conceivable that these kind of 
tests are open for anxiolytic and amnestic effects. 
Relationship with GABAAjbenzodiazepine receptors. 
After establishing the model of investigation, the mechanism by which 
baclofen exerts its effect was investigated. Benzodiazepines mediate their 
anxiolytic effect via facilitating the interaction of GABA with the GABAA 
receptor. Therefore, if a benzodiazepine and a GABAB agonist are active in the 
same model, three possibilities exist: a/ A shared pathway via the GABAA 
receptor, b/ via the GABAB receptor or, cj two differents mechanisms with the 
same behavioural result. The investigation of the first possibility, to 
establish whether the effect of baclofen on extinction is related with the 
GABAAjbenzodiazepine receptor chloride channel complex, is described in 
chapter II and V. This possibility had to be considered because of a number of 
reasons: l/ Benzodiazepines are indirect GABAA agonists and also enhance 
extinction .. 2/ GABAB receptor activation is reported to modulate the release 
of GABA itself (for references see chapter V), and some groups reported an 
increase of release which would mean that baclofen is also an indirect GABAA 
agonist. 3/ Baclofen is reported to enhance binding of benzodiazepine 
receptors ex vivo (Gallager et al. (1978), Rago et al. (1986)). 
In vitro investigations of Majewska and Chuang (1984), Karobath and Sperk 
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(1979) and Ketelaars et al. (chapter II) have shown that GABAB receptor 
activation does not affect binding to the benzodiazepine receptors, which 
makes a direct interaction between baclofen and the GABAA/benzodiazepine 
receptor chloride channel complex unlikely. Also, a clear indirect ex vivo 
effect of baclofen on benzodiazepine receptor binding could not be shown 
(chapter II). Although an increase in number of cerebellar benzodiazepine 
receptors was found in the presence of bicuculline, no effect was present in 
cortical tissue and in cerebellar tissue without bicuculline addition to the 
incubation media. The second possibility, an effect of benzodiazepine receptor 
activation on GABAB receptors, is highly unlikely since it is reported that 
benzodiazepines do not affect binding of GABA to the GABAB receptor, (Majewska 
and Chuang (1984)), and it is firmly established that benzodiazepines affect 
GABAA receptor activation via an allosteric modulation, and not via GABA 
release, uptake or catabolism (review: Tallman et al. (1980)). 
Definite evidence for the non-involvement of the GABAA receptor in the 
effect of baclofen on extinction is presented in the in vivo study described 
in chapter V. The oxazepam- induced extinction of conflict behaviour was 
antagonized by the GABAA antagonist bicuculline. This was also shown for the 
anti-conflict effect of oxazepam, using the same dose regimen for bicuculline 
(unpublished results). In contrast, the effect of baclofen on extinction was 
not blocked by bicuculline. Taken together, it can be concluded that 
benzodiazepines enhance extinction via an enhanced function of GABAA 
receptors, while baclofen acts in a GABAA-independent way via activation of 
GABAB receptors. 
5-HT relationship. 
There are numerous thinkable mechanisms by which baclofen may enhance 
extinction of conflict behaviour. For instance, it is known that GABAB 
receptor activation modulates the activity of several neurotransmitter systems 
(chapter I). It is of interest to investigate whether the anxiolytic effect of 
GABAB receptor stimulation is exerted via modulation of other systems, since 
this would add to the knowledge about the possible role of various neuro-
transmitter systems in (panic) anxiety. The present investigation has focussed 
on the 5-HT system. The reasons for this choice have been described in chapter 
III, IV and V, they concern the anxiolytic properties of 5-HT modulating 
compounds and the relationship between the GABAB receptor and the 5-HT system. 
In animal models for anxiety, it is generally assumed that a decreased 
function of the 5-HT system exerts anxiolytic effects and an increased 
activity exerts an anxiogenic effect. GABAB receptor activation decreases the 
firing rate of 5-HT neurons and reduces the release of 5-HT (see paragraph 
1. 2. 3.). If it is postulated that baclofen affects extinction of conflict 
behaviour via an impaired 5-HT function, a number of experiments can be 
performed to support this hypothesis. a: Inhibition of biosynthesis, b: 
activation of autoreceptors, as well as c: postsynaptic 5-HT receptor 
antagonism should m~m~c the effect of baclofen on extinction. PCPA (p-
chlorophenylalanine, an inhibitor of biosynthesis of 5-HT) and 8-0H-DPAT 
(autoreceptor agonist) indeed enhance extinction of conflict behaviour 
(chapter IV). Additional evidence for the suggestion that baclofen and 8-0H-
DPAT enhance extinction via a decrease in 5-HT release is provided by the 
finding that PCPA pretreatment prevents an additional increase of extinction 
induced by baclofen and 8-0H-DPAT (chapter IV). The observation that 
fluvoxamine (a selective 5-HT reuptake inhibitor) counteracts the baclofen-
induced extinction also supports the 5 -HT hypothesis. However, the lack of 
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effect of fluvoxamine on the 8-0H-DPAT-induced extinction needs explanation 
(see below). An interesting synergism on sedation (in contrast to the blocked 
extinction) is observed after combined treatment of rats with baclofen and 
fluvoxamine (chapter V). As far as it is known at the moment, postsynaptically 
localized receptors are of the 5-HTlA, 5-HTlB and 5-HT2 type. The localization 
of 5-HTlc, 5-HTlD and 5-HT3 receptors in the synaps is unknown (see paragraph 
1.4.2.). In chapter II, III and IV it is shown that 5-HTlc, 5-HT2 and 5-HT3 
blockade does not enhance extinction of conflict behaviour. In contrast, 5-HTl 
blockade by propranolol enhances extinction, while the selective ~­
adrenoceptor blockers butoxamine and metoprolol were not active (chapter IV). 
5-HTl receptors are present on pre- and postsynaptical sites. Since 
propranolol was shown to antagonize the postsynaptically 5-HTlA receptor-
induced 5-HT behaviour in the same dose range as the range in which this drug 
enhanced extinction (chapter IV), a decreased activation of postsynaptic 5-HTl 
receptors might explain the observed effects of propranolol and baclofen on 
extinction of conflict behaviour. This hypothesis receives support from other 
findings: Den Boer (1988) suggested that desensitization of postsynaptic 5-HTl 
receptors underlies the effect of fluvoxamine on panic disorder. In addition, 
it is reported by Moser et al. (1988) that MDL 73005EF, a selective 5-HTlA 
antagonist, exerted anxiolytic effects in several animal models for anxiety. 
It is tentative to suggest that this antagonist mediates its anxiolytic effect 
via blockade of postsynaptic 5 -HTlA receptors. This is supported by the 
finding that the described anxiolytic effect could be antagonized by 
relatively high doses of 8-0H-DPAT (Moser et al. (1988)). This implicates that 
activation of at least a subgroup of postsynaptic 5-HT1 receptors should exert 
an anxiogenic effect. This has actually been described for several 5-HTl 
receptor agonists like RU 24969, mCPP and TFMPP in animal models for anxiety 
(reviews: Broekkamp and Jenck (1989), Chopin and Briley (1987)). Furthermore, 
it is shown by Engel et al. (1984) that 8-0H-DPAT has an anxiogenic effect in 
an animal model of anxiety after pretre.atment of the rats with PCPA. The 
latter treatment was suggested to cause a supersensitivity of postsynaptic 
(anxiogenic) 5-HTlA receptors. Finally, administration of the 5-HTl receptor 
agonist mCPP is reported to elicit anxiety and panic in panic disorder 
patients (Kahn et al. (1988a)). 
Although conflicting data exist, it is assumed that acute administration of 
a 5-HT reuptake inhibitor like fluvoxamine increases postsynaptic 5-HT 
receptor activation (see paragraph 1.4.3.). If this holds truth, such a drug 
should evoke an anxiogenic effect after acute administration, as has been 
shown to occur in patients suffering from panic disorder. It is shown in 
chapter V that fluvoxamine does not enhance extinction after acute 
administration, nor does it decrease extinction in rats with a lower level of 
conflict. The failure to detect an anxiogenic effect on extinction may depend 
on the model used, since anxiogenic responses in animal models of anxiety have 
been reported after administration of several selective 5-HT reuptake 
inhibitors (Chopin and Briley (1987)). However, fluvoxamine has an anxiolytic 
action in the defensive burying test and the four plates test (see paragraph 
1. 6.). 
If the effect of baclofen on extinction of conflict behaviour is somehow a 
reflection of its anti-panic efficacy, long-term administration of 
fluvoxamine, another anti-panic drug, should also enhance extinction of 
conflict behaviour. It is shown in chapter V that enhancement of extinction is 
not accomplished on the 8th and 13th day, but is indeed present at the 16th 
day, 2 days after terminating the fluvoxamine treatment. Since it is 
postulated that the anxiolytic effect of fluvoxamine is caused by an adaptive 
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mechanism after long-term administration, it is conceivable that this adaptive 
mechanism only occurred after a longer period than 13 days, and is still 
present 2 days after terminating the fluvoxamine administration. This would be 
in accordance with the findings of Fontana et al. (1989), who reported a delay 
in anxiolytic action during treatment with anti-depressants of 2 to 4 weeks. 
It is reported that long-term treatment with anti-depressants causes an 
upregulation of GABAB receptor number and function. In contrast, 5-HTlA 
receptor binding and function are decreased after the same treatment (see 
paragraph 1.3.). In order to find out whether these findings can be 
generalized to the anxiolytic effect of GABAB and 5-HTlA receptor activation, 
the effect of baclofen and 8-0H-DPAT on extinction were monitored during and 
after fluvoxamine treatment (chapter V). As in the acute experiments, an 
increased sedation could be observed with combined treatment of baclofen and 
fluvoxamine in the first two weeks. After termination of fluvoxamine 
administration, the baclofen-induced sedation was again increased, the latter 
effect might reflect GABAB receptor upregulation. It was shown that the 
effects of baclofen on extinction were counteracted on the 8th and 13th day 
(again in analogy with the acute experiments), but showed a sharp increase 
after termination of fluvoxamine. Unfortunately, since the level of 
statistical significance was not reached in the extinction experiments with 
baclofen, definite conclusions about GABAB upregulation after long-term 
fluvoxamine can not be drawn at this moment. 
The reported results on desensitization of presynaptic 5-HTlA receptor 
number and function (paragraph l. 3.) could not be shown using 8-0H-DPAT-
induced extinction of conflict behaviour. As in the acute experiments using 
fluvoxamine and 8-0H-DPAT, this lack of effect of chronic fluvoxamine on the 
8-0H-DPAT induced extinction needs explanation. Several possible explanations 
can be brought forward: An anxiolytic effect of 8-0H-DPAT via a subgroup of 
postsynaptic 5-HTlA receptors which do not desensitize after fluvoxamine. This 
would implicate that activation of postsynaptic 5-HTlA receptors may not only 
exert anxiogenic effects, but also anxiolytic effects. This latter effect 
might be exerted by the 5-HTlA receptors with an inhibitory effect on 
hippocampal activity (see paragraph 1.4.2. and 1.4.4.). Neurochemical data 
indicate that 5-HTlA receptor activation has two opposite effects on the 
activity of adenylate cyclase in the rat hippocampus (Devivo and Maayani 
(1986)). It is tentative to suggest that these neurochemical effects underly 
an anxiogenic and anxiolytic effect induced by 5-HTlA receptor stimulation. 
Other explanations for the lack of effect of fluvoxamine on the 8-0H-DPAT-
induced extinction are also possible: Although a dose of 10 mgjkg counteracted 
the effects of oxazepam and baclofen, it is conceivable that higher acute and 
chronic doses of fluvoxamine were necessary in order to counteract the effect 
of 8-0H-DPAT. Finally, administration of fluvoxamine by mlnl-pump might exert 
different effects on receptor number and/or function than the more usual twice 
or once daily injections. 
In conclusion, the present experiments strongly suggest that the impairment 
of the 5-HT system, (more precisely, a decreased activation of postsynaptic 5-
HTl receptors) plays a role in the effect of baclofen on extinction of 
conflict behaviour. However, this does not implicate that there are no other 
neurotransmitters systems (e.g. noradrenergic system, glutaminergic system) by 
which baclofen might affect anxiety. 
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APPENDIX 
AN INTEGRATION OF THE PRESENT INVESTIGATIONS INTO THE EXISTING CONCEPTS OF 
ANXIETY DISORDERS. 
In a review on the phenomenology of panic disorder, Mavissakalian (1988) 
tentatively postulates that a panic attack is partly a cognitive phenomenon, 
which is triggered in anxiety prone subjects by aspecific increases in 
physiological arousal. On its turn, the anxiety proneness is for a great part 
a genetically transferred phenomenon. The view of Mavissakalian on anxiety 
disorders is characterized by the notion that the various DSM based syndromes 
are gradual manifestations of the same constitutional "anxious" 
predisposition. Gray (1988) and Gorman et aL (1989) describe the 
neurochemical and neuroanatomical substrate of this "anxious" predisposition 
and its resulting anxiety disorders; they postulate that the key structure is 
formed by the septohippocampal system, in which the noradrenergic and 5-HT 
system play the most important role. The onset of panic attacks is provoked by 
hyperactivity in the brain stem, where the cell bodies of the 5-HT and 
noradrenergic neurons originate. The anxiolytics exert their action by 
impairing the function of these structures, (i.e. reduction of input from 
locus ceroeleus or raphe nuclei to their projection sites). The septo-
hippocampal system functions as a "comparator", it receives sensory input and 
compares it with memory of equivalent situations. If input from the locus 
ceroeleus and raphe nuclei is increased, the capacity of the septohippocampal 
system as a comparator is increased. It might be this area which produces the 
anticipatory anxiety, since the "scanning" which results from this "comparing" 
activity seems alike with the symptoms of the patient in this particular form 
of anxiety. It is reasoned that the anticipatory anxiety would than persist 
after the panic attack as a result of a kindling phenomenon. The cognitive 
value which is adhered to the sensory input lies more beyond the 
septohippocampal system, e.g. the prefrontal cortex. It is postulated that 
avoidance behaviour has its root in these areas. It has to be remarked here 
that this theory considers avoidance behaviour as a cognitive/learned response 
on the panic attacks. However, opposing views on the latter notion exist, as 
is pointed out in paragraph 1. 7. . In a further attempt to synthetize the 
concepts of Mavissakalian, Gorman and Gray on anxiety, it might be postulated 
that subjects are more prone to become anxious if their constitutional factors 
somehow cause an hyperfunction of the septohippocampal system (e.g. 
supersensitive 5-HTl receptors, subsensitive a2-adrenoceptors and subsensitive 
GABAB receptors). 
Several drugs of different classes are reported to be active on all 
components of panic disorder. This is shown for anti-depressants, (of which 
the 5-HT reuptake inhibition seems to correlate with the anxiolytic action), 
baclofen, alprazolam, or high doses of more current benzodiazepines. In 
addition, several classes of pharmaca are reported to elicit (panic) anxiety: 
lactate infusion, caffeine, ~-carbolines (benzodiazepine inverse agonists), 
isoproterenol,' yohimbine, COz inhalation and 5-HT system activation. 
If one assumes that the neurochemically-based "key" component in the 
pathophysiology of (panic) anxiety is related with the septohippocampal 
system, all the above-mentioned therapeutic drugs shoulf affect this "key" 
component. On first sight, all drugs affect the function of the 5-HT system 
85 
and the noradrenergic system (see chapter I). It has to be noted that a 
reduction in activity of only one system does not induce a complete relief for 
the panic disorder patient, since the three 5-HT autoreceptor agonists 
buspirone, ipsapirone and gepirone only affect anticipatory anxiety (paragraph 
1.4.4.), and clonidine has only transient and weak anxiolytic effects 
(paragraph 1. 5 .1.). The same picture arises for blockade of postsynaptic 
receptors of one neurotransmitter system: It is shown that antagonism of 5-HTz 
receptors by the selective antagonist ritanserin does not reduce anxiety in 
panic disorder (Den Boer (1988)). No data are available yet about the specific 
anxiolytic effects of 5-HT3 antagonists. Den Boer (1988) has postulated that 
desensitization of postsynaptic 5-HT1 receptors may play a role in the anti-
panic effects of fluvoxamine. This is supported by a few reports of positive 
effects of propranolol on panic anxiety but conflicting reports exist, and the 
consensus is that propranolol has no anti-panic properties (Munj ack et al. 
(1989)). Still, propranolol is an interesting agent since it is a blocker of 
both f>-adrenoceptors and 5-HTl receptors although it is not clear whether 
propranolol is used in patients at doses which indeed block 5-HTl receptors. A 
putative anti-panic effect of postsynaptic blockade of both f>-adrenoceptors 
and 5-HTl receptors remains an interesting hypothesis until selective 
(postsynaptic) 5-HTl antagonists are available for clinical studies. 
Since impairment of function of one of the two neurotransmitter systems 
provides no complete relief for the patient suffering from panic disorder, it 
might be suggested that the more complete anti-panic properties of the drugs 
mentioned below result from a combined effect on both the noradrenergic and 5-
HT system: 
Baclofen: Baclofen decreases noradrenergic system activity and also 
modulates the 1)-adrenoceptor-coupled adenylate cyclase system. In addition, it 
inhibits release at the projection sites of the 5-HT system and is closely 
related to the 5-HTlA receptor at presynaptic and postsynaptic sites. The 
effect of baclofen on anticipatory anxiety might be explained by its effect on 
the 5-HT system function while the action of baclofen in the locus ceroeleus, 
its "fine tuning" of the f>-adrenoceptor function in the frontal cortex, and 
its postsynaptic inhibitory effect in the hippocampus might play an important 
role in the effect of baclofen on panic attacks and avoidant behaviour. 
Alprazolam and high doses of 1.4 benzodiazepines: The benzodiazepines 
decrease the activity of the 5-HT and noradrenergic system in the raphe nuclei 
and locus ceroeleus respectively (paragraph 1. 2. 3.). High affinity 
benzodiazepines such as alprazolam have a more powerful effect on these 
systems. The decrease in activity of the 5-HT system may account for the 
described effects on anticipatory anxiety. The effect of alprazolam and high 
doses of other benzodiazepines on panic attacks and avoidant behaviour might 
be explainable by several observations: It has been reported that high doses 
of benzodiazepines decrease release of noradrenaline in the hippocampus and so 
mimicked the effect of baclofen in the same experiment (Fung and Fillenz 
(1983)). Secondly: Alprazolam appears to be linked to the a2-adrenoceptor 
(Eriksson et al. (1986)). 
Selective 5-HT reuptake inhibitors: These compounds modulate the number 
and function of pre- and postsynaptic 5-HT receptors, f>-adrenoceptors and 
GABAB receptors. It is not inconceivable that the antidepressant-induced 
postsynaptic 5-HTl receptor desensitization accounts for their effect on 
anticipatory anxiety. The effect of anti-depressants on panic attacks and 
avoidant behaviour might be mediated via the combined effect of GABAB receptor 
upregulation, 5-HT receptor downregulation and adrenoceptor downregulation. 
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In conclusion, data derived from the present experiments combined with 
existing concepts of anxiety disorders lead to the suggestion that the total 
effect on panic disorder of the above-mentioned agents might be caused by a 
summation of their effects on both the 5-HT and noradrenergic system. 
87 
References 
Audi EA and Graeff FG (1987) GABAA receptors in the midbrain central grey 
mediate the antiaversive action of GABA. Eur J Pharmacol 135:225-229. 
Allikmets and Rago (1988) abs Capo Boi conference 
Bartus RT, Dean RL and Flicker C (1987) Cholinergic psychopharmcology: an 
integration of human and animal research on memory. In: Psychopharmacology: 
The Third Generation of Progress. Ed Meltzer HY pp 219-232 Raven Press, New 
York. 
Bowery NG, Hill DR and Hudson AL (1982) Evidence that SL75102 is an agonist at 
GABA-b as well as GABA-a receptors. Neuropharmacol 21:391-405 
Broekkamp CL, Berendsen HH, Jenck F and Van Delft AM (1989) Animal models for 
anxiety and response to serotonergic drugs. Psychopathology 22 Suppl 1:2-12 
Chopin P, Briley M (1987) Animal models of anxiety: the effect of compounds 
that modify 5-HT neurotransmission. TIPS 8:383-388 
Den Boer JA (1988) PhD thesis. Serotonergic mechanisms in anxiety disorders. 
An inquiry into serotonin function in panic disorder. 
Engel JA, Hjorth S, Svensson K et al (1984) Anticonflict effect of the 
putative serotonin receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin 
(8-0H-DPAT). Eur J Pharmacol 105:365-368 
Eriksson E, Carlsson M, Nilsson C and Soderpalm B (1986) Does alprazolam, in 
contrast to diazepam, activate alpha2-adrenoceptors involved in the 
regulation of growth hormone secretion? Life Sci 38:1491-1498 
Fontana DJ, Carbary TJ and Commissaris RL (1989) Effects of acute and chronic 
anti-panic drug administration on conflict behaviour in the rat. 
Psychopharmacol 98:157-162. 
Gallager DW, Thomas JW and Tallman JF (1978) Effect of GABAergic drugs on 
benzodiazepine biding site sensitivity in rat cerebral cortex. Biochem. 
Pharmac. 27:2745-2749. 
Gorman JM, Liebowitz MR, Fyer AJ and Stein J (1989) A neuroanatomical 
hypothesis for panic disorder. Am J Psychiat 146:148-161. 
Gray JA (1988) A neuropsychological approach to anxiety disorders. In: 
Depression, anxiety and aggression. Eds Swinkels JA and Blijleven W, 
Medididact, Houten. 
Gray JA, Goodwin GM, Heal DJ and Green AR (1987) Hypothermia induced by 
baclofen, a possible index of GABAB receptor function in mice, is enhanced 
by antidepressant drugs and ECS. Br J Pharmac 92:863-870 
Kahn RS, Asnis GM, Wetzler S and van Praag M (1988b) Neuroendocrine evidence 
for serotonin receptor hypersensitivity in panic disorder. Psychopharmacol 
96:360-364 
Kahn RS, van Praag HM, Wetzler S, Asnis GM and Barr G (1988a) Serotonin and 
anxiety revisited. Biol Psychiat 23:189-208 
Karobath M and Sperk G (1979) Stimulation of benzodiazepine receptor binding 
by T-aminobutyric acid. Proc. Natl. Acad. Sci. USA 76:1004-1006. 
Majewska MD and Chuang DM (1984) Modulation by calcium of T-aminobutyric acid 
(GABA) binding to GABAA and GABAB recognition sites in rat brain. Mol 
Pharmacol 25:352-359 
Mavissakalian M (1988) The diagnosis and treatment of anxiety disorders. In: 
Depression, anxiety and aggression. Eds Swinkels JA and Blijleven W, 
Medididact, Houten. 
Moser P, Hilbert M, Middlemiss, et al. (1988) Effects of MDL 73005EF in animal 
models predictive of anxiolytic activity. Br J Pharmacol C3 
Pepplinkhuizen L and Bruinvels J (1978) Effect of baclofen in patients 
88 
suffering from anxiety neurosis. Abs IInd World Congress of Biological 
Psychiatry pl56. 
Rago LK, Kiivet RAK, Harro JE and Allikmets LKh (1986) Benzodiazepine binding 
sites in mice forebrain and kidneys: evidence for a similar regulation by 
GABA agonists. Pharmacol Biochem Behav 24:1-3 
Suzdak PD and Gianutsos G (1986) Effect of chronic imipramine or baclofen on 
GABA-B binding and cyclic AMP production in cerebral cortex. Eur J Pharmac 
131:129-133 
Tallman JF, Paul SM, Skolnick P and Gallager DW (1980) Receptors for the age 
of anxiety: pharmacology of the benzodiazepines. Science 207:274-281. 
Wander TJ, Nelson A, Okazaki Hand Richelson E (1987) Antagonism by 
neuroleptics of serotonin 5-HTlA and 5-HT2 receptors of normal human brain 
in vitro. Eur J Pharmacol 143:279-282 
89 
SUMMARY 
The observation that the GABAB receptor agonist baclofen (Lioresal) has 
anxiolytic properties in man formed the basis of the present investigations 
into the mechanism responsible for the anxiolytic effect of this drug. 
Baclofen is not active in the Geller-Seifter conflict test, which is a classic 
animal model for anxiety. Therefore a model had to be developed in order to 
study this compound. Since baclofen has a beneficial effect not only on panic 
attacks, but also on anticipatory anxiety and phobic avoidance, the Geller-
Seitter test was modified in such a way that the new test might be a putative 
animal model for the latter two forms of anxiety in man. It is described that 
conflict behaviour in the Geller-Seifter test shows a slow extinction after 
removal of foot-shock punishment, enhancement of this process in rats might 
reflect the disappearance, or decrease, of anticipatory anxiety and phobic 
avoidance in man. 
The first chapter reviews the literature on the neurotransmitters which are 
somehow connected with anxiety. The emphasis lies on the GABAergic, 
serotonergic and noradrenergic system. Receptor types, second messengers, 
neurotransmitter interrelationships, effect of anti-depressants, animal models 
for anxiety and panic disorder are described. 
Chapter II describes extinction of conflict behaviour as an animal model 
for anxiety. Baclofen, benzodiazepines and haloperidol enhance extinction of 
conflict behaviour while only the benzodiazepines have an anti-conflict 
action. Baclofen enhances punished drinking in Vogel's test. It is shown via 
in vitro and ex vivo receptor binding experiments that the anxiolytic effect 
of baclofen is probably not mediated via the GABAA/benzodiazepine receptor 
chloride channel complex. 
In the third chapter, it is shown that the 5-HT2 antagonist ritanserin is 
not active on extinction and conflict behaviour with foot shock punishment. In 
contrast, anti-cholinergic compounds have an anti-conflict effect and increase 
extinction. It is not inconceivable that a mixture of anxiolytic effects and 
effects on retrieval of memory for aversive events are responsible for the 
activity of these compounds. 
Chapter IV describes the experiments which investigate the activity of 
several 5-HT modulating compounds on extinction of conflict behaviour. It is 
shown that impairment of the 5-HT function via biosynthesis inhibition (PCPA), 
autoreceptor activation (8-0H-DPAT) and postsynaptic 5-HTl receptor blockade 
(propranolol) enhance extinction of conflict behaviour without affecting 
conflict behaviour itself. Blockade of 5-HT3 receptors and f;)-adrenoceptors 
does not affect extinction of conflict behaviour or conflict behaviour with 
foot shock. In addition, it is shown that in PCPA pretreated rats, baclofen 
and 8-0H-DPAT do not enhance extinction above the level of extinction induced 
by PCPA alone. These data suggest that impairment of the 5-HT system, or more 
precisely: reduced postsynaptic 5-HTl receptor stimulation, plays a role in 
the baclofen-induced extinction. 
In the fifth chapter, conclusive evidence is shown that baclofen enhances 
extinction in a GABAA-independent way, since the effect of baclofen on 
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extinction is not antagonized by the GABAA antagonist bicuculline. In 
contrast, bicuculline antagonizes the oxazepam- induced anti-conflict effect 
and the oxazepam-induced extinction of conflict behaviour. Acute 
administration of the selective 5-HT reuptake inihibitor fluvoxamine 
counteracts both the oxazepam and baclofen-induced extinction. This supports 
the suggestion that the latter effect of baclofen is caused by an impairment 
of the 5-HT system. However, the 8-0H-DPAT-induced extincion was not 
counteracted with the same dose of fluvoxamine. Long-term administration of 
fluvoxamine enhances extinction of conflict behaviour. Since it is reported 
that long-term administration of anti-depressants results in an upregulation 
and downregulation in number and function of GABAB receptors and 5-HTl 
receptors respectively, the effect of baclofen and 8-0H-DPAT on extinction was 
observed during and after two weeks of fluvoxamine administration. The 
reported upregulation of GABAB receptor sites seems to be supported by the 
present experiments while, in analogy with the acute experiments, the effect 
of 8-0H-DPAT on extinction was not affected by fluvoxamine. The implications 
of these data were discussed. 
The present data suggest an important role of an impairment of the 5 -HT 
system, especially reduced activation of the postsynaptic 5-HTl receptor, in 
the baclofen-induced extinction of conflict behaviour. It is tentative to 
suggest that this mechanism also plays an important role in aspects of the 
anxiolytic action of this drug in panic disorder. In the appendix of chapter 
VI, an effort was made to make a synthesis of the present results and existing 
theories on the pathofysiology of anxiety in panic disorder. A speculative 
hypothesis is described of the neurochemical mechanism behind the effects of 
baclofen, anti-depressants and alprazolam on panic attacks, anticipatory 
anxiety and avoidant behaviour. 
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SAMENVATTING 
De paniekstoornis is een ernstige angststoornis die niet (genoeg) op de 
gebruikelijke angstdempende medicatie, de benzodiazepines, reageert. Deze 
angststoornis is vaak opgebouwd uit drie componenten: de paniekaanvallen zelf, 
de anticipatoire angst (angst voor toekomstige paniekaanvallen samengaand met 
een algemeen verhoogd angstniveau) en het vermijdingsgedrag (agorafobie, angst 
om in een situatie te komen waar geen adequate hulp voorhanden is ingeval er 
een paniekaanval start). Aangezien de benzodiazepines in eerste instantie hun 
werking uitoefenen via de neurotransmitter GABA, leek de redenatie van een 
tekort aan GABA bij deze patienten logisch. Vanuit die redenering is er in 
1978 door Pepplinkhuizen en Bruinvels een klinisch onderzoek gestart met 
baclofen (Lioresal), een GABA-analoog. Baclofen bleek op alle componenten van 
de paniekstoornis een gunstige uitwerking te hebben. 
Deze klinische observatie leidde tot dit promotieonderzoek naar het 
mechanisme achter het anxiolytische effect van baclofen. Om dit onderzoek met 
proefdieren (ratten) te verrichten moest een diermodel voor angst ontworpen 
worden waarin ook baclofen een effect zou hebben. Het is gebleken dat baclofen 
geen effect vertoont in een klassiek diermodel voor angst, de Geller-Seifter 
test. Deze test meet gedrag bij dorstige ratten die in conflict zijn tussen 
hun dorst enerzijds en de angst om een lichte electrische schok te ontvangen 
bij het daadwerkelijke drinken anderzij ds. Aangezien de rat in conflict is 
tussen zijn dorst en zijn angst voor de schok, noemt men het gedrag tijdens de 
test "conflictgedrag". Omdat baclofen niet alleen een effect heeft op de 
paniekaanvallen maar ook op de andere twee componenten van de paniekstoornis, 
werd de Geller-Seifter test gewijzigd, en wel in die zin dat de rat de 
electrische schok wel verwacht doch zonder dat die schok in de testsituatie 
aanwezig is. Indien dit een langere tijd het geval is, ebt het conflictgedrag 
langzaam weg, dit wordt "extinctie van conflictgedrag" genoemd. Hoewel het 
niet is toegestaan om in antropomorfische termen te denken bij diermodellen, 
is het verleidelijk om de analogie aan te duiden tussen deze "angst voor de te 
verwachten schok" van de rat en de anticipatoire angst van de patient, en 
tussen "het achterwege laten van het gedrag dat leidt tot een electrische 
schok" van de rat en de agorafobie van de mens. Extinctie van conflictgedrag 
wordt door baclofen versneld, en is verder als model gebruikt om het 
anxiolytische effect van baclofen te bestuderen. 
In hoofdstuk I wordt de literatuur over de met angst gerelateerde 
neurotransmittoren doorgenomen. De nadruk wordt gelegd op GABA, serotonine en 
noradrenaline. Aandacht wordt geschonken aan anti-depressiva (welke ook een 
gunstig effect hebben op de paniekstoornis), de verschillende diermodellen 
voor angst, en de paniekstoornis zelf. Aangezien de literatuurgegevens daar 
het meeste aanleiding toe gaven, werd besloten om het onderzoek met name te 
richten op eventuele effecten van baclofen op het GABAA/benzodiazepine 
receptor complex en het serotonerg systeem. 
Hoofdstuk II legt de basis voor de rechtvaardiging van het gebruik van 
extinctie van conflictgedrag als diermodel voor angst. Het bleek dat baclofen, 
benzodiazepines en haloperidol extinctie versterken. Er werden in vitro en ex-
vivo receptor binding experimentem uitgevoerd, welke aantoonden dat het 
angstdempende effect van baclofen niet via het GABAA/benzodiazepine systeem 
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wordt uitgeoefend. 
In het derde hoofdstuk blijkt dat cyproheptadine, een serotonine2 en 
muscarine receptor blokker, ook extinctie van conflictgedrag versnelt en dat 
dit via zijn muscarine blokkade bewerkstelligd wordt. Niet uitgesloten kan 
worden dat het hier om een gemengd anxiolytische en geheugenverstorende 
werking van deze stof gaat. 
Hoofdstuk IV beschrij ft het onderzoek naar middelen welke de functie van 
het serotonerg systeem verminderen. Uit het onderzoek bleek dat vermindering 
van serotonine biosynthese, vermindering van serotonine afgifte, en blokkade 
van postsynaptische serotoninel receptoren een versnelde extinctie 
veroorzaakt. Blokkade van serotonine3 receptoren heeft geen effect. Tevens 
bleek, dat bij een verminderde serotonine biosynthese geen extra effect meer 
op extinctie verkregen werd na baclofen of een serotonine afgifte remmer. Deze 
resultaten suggereren een effect van baclofen op extinctie via een verminderde 
functie van het serotonerge systeem. Met name de verminderde postsynaptische 
activatie van serotonine1 receptoren zou ten grondslag kunnen liggen aan het 
effect van baclofen. 
In het vijfde hoofdstuk wordt nu ook in vivo aangetoond dat baclofen niet 
via activatie van het GABAA/benzodiazepine systeem kan werken, aangezien de 
GABAA blokker bicuculline het effect van baclofen niet tegengaat, terwij 1 
bicuculline het effect van oxazepam, een benzodiazepine, wel tegengaat. De 
relatie tussen baclofen en het serotonerge systeem werd verder uitgediept door 
te kijken naar het effect dat de selectieve serotonine heropnameremmer 
fluvoxamine uitoefent op het effect van baclofen, de serotonine afgifteremmer 
8-0H-DPAT en oxazepam. Het effect van fluvoxamine is zowel na acute toediening 
als na chronische toediening bestudeerd. Fluvoxamine heeft klinisch een 
anxiolytische werking na verloop van enkele weken. Het blijkt dat fluvoxamine 
het effect van baclofen en oxazepam op extinctie tegengaat, hetgeen de 
suggestie van een relatie tussen baclofen en oxazepam enerzijds en het 
serotonine systeem anderzijds steunt. Na chronische toediening van fluvoxamine 
heeft fluvoxamine zelf een kortdurend effect op extinctie. Bovendien is het 
effect van baclofen op extinctie licht versterkt, een effect dat al door 
andere groepen met behulp van andere diermodellen werd aangetoond. Een ander 
beschreven effect na een wat langere toediening van fluvoxamine, namelijk een 
vermindering van effect van 8-0H-DPAT, bleek niet aanwezig te zijn. De 
betekenis hiervan wordt nader besproken in de discussie van het hoofdstuk. 
De verkregen resultaten suggereren een belangrijke rol van een verminderde 
functie van het serotonerg systeem, in het bijzonder een verminderde activatie 
van de postsynaptische serotonine1 receptor, bij het effect van baclofen op 
extinctie van conflictgedrag. Het is verleidelijk om een analogie te trekken 
met het effect van baclofen op de paniekstoornis bij de mens, zeker omdat er 
reeds theorieen en bewij smateriaal bestaan over de betrokkenheid van het 
serotonerge systeem bij paniekstoornis. Met behulp van bestaande theorieen 
wordt de implicatie van de verkregen resultaten nader besproken in de algemene 
discussie en appendix. 
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